

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Equivalent health status for e-learning, group training self-management or usual care in oral anticoagulation patients: a parallel cohort design in the PORTALS Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017909
Article Type:	Research
Date Submitted by the Author:	29-May-2017
Complete List of Authors:	Talboom-Kamp, Esther; LUMC, Public Health and Primary Care Department; SALTRO Diagnostic Centre, Verdijk, Noortje; LUMC, Public Health and Primary Care Department; SALTRO Diagnostic Centre, Kasteleyn, Marise; LUMC, Public Health and Primary Care Department Harmans, Lara; SALTRO Diagnostic Centre, Talboom, Irvin; Zorgdraad Foundation Numans, Mattijs; LUMC, Public Health and Primary Care Department Chavannes, Niels; LUMC, Public Health and Primary Care Department
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Health informatics, Medical education and training
Keywords:	self-efficacy, eHealth, TTR, self-management, thrombosis, oral anticoagulation

SCHOLARONE™
Manuscripts

only

1
2
3
4 Equivalent health status for e-learning, group training self-
5
6 management or usual care in oral anticoagulation patients: a parallel
7
8 cohort design in the PORTALS Study
9
10

11
12
13
14 EPWA Talboom-Kamp MD MBA^{1,2}, NA Verdijk MSc PhD^{1,2}, MJ Kasteleyn MSc PhD¹, LM Harmans MSc²,
15 IJSH Talboom³, ME Numans MD PhD¹, NH Chavannes MD PhD¹
16
17

18
19 ¹Leiden University Medical Centre, Public Health and Primary Care Department
20 P.O. Box 9600, 2300 RC Leiden, the Netherlands
21

22
23
24 ²Saltro Diagnostic Centre
25 Mississippidreef 83, 3565 CE Utrecht, the Netherlands
26

27
28
29 ³Zorgdraad Foundation
30 Wijnand van Arnhemweg 54, 6862XN Oosterbeek, the Netherlands
31

32
33
34 **Corresponding author**

35 EPWA (Esther) Talboom-Kamp MD MBA
36
37 Saltro Diagnostic Centre
38
39 Mississippidreef 83
40
41 3565 CE Utrecht
42
43 The Netherlands
44
45 Telephone: +31-30-2361170
46
47 Fax: +31-30-2361172
48
49 E-mail: e.talboom@saltro.nl
50
51
52
53
54
55
56
57
58
59
60

PORTALS study

Abstract

Objectives To analyze the effect on health status and self-management skills of the implementation of self-management programs, including eHealth by e-learning versus group training.

Setting A primary Care Thrombosis Service Center.

Participants Of the 247 OAT patients, 63 started a self-management program by e-learning, 74 self-management by group training, and 110 received usual care.

Intervention and methods Parallel cohort design with two randomized self-management groups (e-learning and group training) and a third group receiving usual care. Multilevel linear regression modeling was used to analyze the effect of implementation of self-management on time in therapeutic range (TTR). Linear regression analysis was used to analyze usage of a supporting eHealth platform and the impact on self-efficacy (Generalized Self-Efficacy Scale; GSES) and education level. After intervention, TTR was measured in 3 time periods of 6 months each.

Main outcome measures These were i) health status (TTR, severe complications), ii) usage of an eHealth platform, and iii) determinants (GSES, education level).

Results Analysis of the three groups showed no significant differences in TTR between the three time periods ($p=0.520$), between the groups ($p=0.460$) or between the groups over time ($p=0.263$). Comparison of e-learning and group training showed no significant differences in TTR between the time periods ($p=0.614$), between the groups ($p=0.460$) or between the groups over time ($p=0.263$). No association was found between GSES and TTR ($p=0.717$), or between education level and TTR ($p=0.107$). No significant difference was found between the two self-management groups in usage of the platform in the three time periods (0-6 months $p=0.571$; 6-12 months $p=0.866$; 12-18 months $p=0.260$).

Conclusions No differences were found between OAT patients trained by e-learning or by a group course regarding health status, TTR, and usage of a supporting eHealth platform. The TTR was similar in both the self-management and regular care patients.

Trial Registration – NTR3947

PORTALS study

1
2
3 **Keywords** – oral anticoagulation; TTR; eHealth; self-management; self-efficacy; e-learning;
4 thrombosis; self-monitoring.
5
6
7
8

9 10 Article summary

11 12 Strengths and limitations of this study

- 13 • This study provides practical insight into successful implementation of self-management
14 programs consisting of high-quality training and usage of a patient platform;
- 15 • The study findings add important evidence to the existing body of knowledge on
16 implementation of eHealth;
- 17 • The needed number of participants was not entirely met in one of the groups;
- 18 • Behavioral changes require time, whereas the study period was restricted to 18 months;
- 19 • Patients were free to volunteer, which might have caused bias in our study groups.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PORTALS study

Introduction

Venous thromboembolism (VTE) and atrial fibrillation (AF) are common causes of mortality and morbidity, with rising prevalence and medical costs [1] [2] [3]. Oral anticoagulation therapy (OAT) reduces thromboembolic events in AF, prosthetic heart valves, acute myocardial infarction and other conditions, and is an effective treatment for VTE [4] [5] [6]. The major risks of OAT are bleeding complications, with a rate of major bleeding among long-term users of vitamin K antagonists (VKAs) of 1.5-5.2% per year [7] [8] [9]. There is a narrow therapeutic range for OAT, expressed as the international normalized ratio (INR); INR values ≥ 4.5 increase the risk of major bleeding and values ≥ 2 increase the risk of thromboembolism [10] [11]. This is relevant, as patients have considerable difficulty in maintaining adequate adherence to VKA regimens, with a significant effect on anticoagulation control [12]. Structured monitoring and coaching of patients using VKA is essential. This may be carried out by specialized centers in primary care or in hospitals [13]. Alternatively, patients might choose to self-manage their VKA monitoring. In the case of OAT, self-management includes monitoring INR values by patients (self-monitoring) and, as a possible next step, self-adjustment of the medication dosage (self-dosage). Nowadays, patients using self-management programs are usually supported by tailor-made eHealth platforms, because eHealth interventions have proven effective in stimulating self-management [14]. Self-management provides more freedom for the patient, improves quality of life and self-efficacy, and lightens the burden of specialized centers [15] [16]. Research shows a reduction of thromboembolic events and a reduction in all-cause mortality for patients with self-management [17]. These improvements are due to the fact that patients have greater responsibility in their disease management together with increased awareness, commitment and interest in their condition [18].

Recently other anticoagulants, novel or non-vitamin K antagonist oral anticoagulants (NOACs), have been introduced and are increasingly preferred as an alternative for VKA as they do not require frequent monitoring [19]. However, data on the effects of NOAC use in routine clinical practice are still lacking, although disadvantages and risks have been reported. Monitoring of kidney function is necessary, and compliance with medication intake is also very important for NOACs [20] [21]. Thus, adequate self-management is important for all patients with OAT, irrespective of the type of medicine they use. Adequate self-management requires individual ability to deal with self-monitoring, symptoms, treatment, and the physical and social consequences of a disease. The basic principle of self-management is that behavioral change cannot succeed without patients accepting their own responsibility; this behavioral change is necessary to improve the quality of life of patients and the primary outcomes of their health and disease [22]. Research on chronic diseases such as PORTALS study

1
2
3 diabetes [23], COPD [24], and heart failure [25] has shown that aspects such as self-efficacy (belief in
4 one's capabilities to organize and execute the course of action required to produce given
5 attainments), educational level, socioeconomic status (SES), age and sex are influencing factors in
6 successful self-management and predictors in eHealth usage [26].
7
8
9

10
11 As education is the basic approach in the development of self-management skills, the strategy used
12 to implement educational support is expected to affect the individual level of self-management and,
13 thereby, clinical outcomes. To test this hypothesis, we designed the PORTALS study. The aim of this
14 study was to analyze the effect of the implementation of a self-management program, including
15 eHealth by e-learning versus a group training. In addition, we aimed to investigate the relationship
16 between the implementation strategy, health status, self-management skills and individual patient
17 characteristics. In the design of the PORTALS study, both self-monitoring and self-dosage of
18 medication are considered important self-management skills.
19
20
21
22
23

24 25 Methods

26 27 Study design

28
29 For the PORTALS study, we designed a quality improvement intervention and compared strategies in
30 an implementation study [27]. Two methods were developed to train long-term OAT patients of the
31 Saltra Thrombosis Service (outpatient anticoagulation clinic and laboratory) in self-management
32 routine care. Using this design, we aimed to examine the influence of the training strategy on clinical
33 outcomes and usage of the supporting eHealth platform. Full methodological details are reported
34 elsewhere [28]; Figure 1 presents an overview of the study design.
35
36
37
38
39

40
41 A parallel cohort design was used to investigate determinants of optimal implementation of self-
42 management by comparing two different training methods. After inclusion, participants were
43 randomly divided into subgroups: one group was trained and educated by e-learning (group 1) and
44 the other group received face-to-face group training (group 2). Patients unable or unwilling to dose
45 their medication were free to continue with only self-monitoring. Patients who did not wish to start
46 with self-management were invited to participate in the non-self-management group, i.e. a parallel
47 cohort group receiving usual care (group 3). Group 3 provided valuable information about the
48 patients who were unable/unwilling to use an online supported self-management program.
49
50
51
52
53
54
55
56
57
58
59
60

PORTALS study

1
2
3 Based on our parallel cohort design, comparison between e-learning and group training for self-
4 management (group 1 and 2) and non-self-management patients (group 3) is applicable, considering
5 the specific conditions in the choice of the statistics.
6
7
8

9 10 Participants

11 The present study focused on patients of the Salthro Thrombosis Service who voluntarily chose to
12 start with self-management. The inclusion criteria for patients to start with self-management were a
13 long-term indication for anticoagulants, internet access, and stable INR values (at least three INR
14 values in succession must be within therapeutic range). Patients who met the criteria for self-
15 management were approached for participation in the study. Because self-management (including
16 eHealth) is already a regular care process of the Salthro Thrombosis Service, the group training was
17 also open to patients who were not willing to participate in the study. The e-learning was reserved
18 for participants of the present study, as this was a new implementation method. All patients
19 provided written informed consent before participation in the study.
20
21
22
23
24
25
26
27

28 Patient involvement

29 Patients were neither involved in the design, nor in defining research questions and outcome
30 measures of the study; however, they were actively involved in the development of the self-
31 management platform Portavita. To maximize the involvement of patients we did not randomize the
32 intervention groups (self-management and usual care); we chose a recruitment design in which
33 patients of the Thrombosis Service voluntarily chose to start with self-management. During the study
34 patients could give feedback on the intervention and on the self-management platform; their
35 satisfaction was continuously monitored. Feedback from patients made it possible to optimize their
36 care. All patients will be informed about the results of this study.
37
38
39
40
41
42
43
44

45 Recruitment of patients and non-participation

46 Patients of the Salthro Thrombosis Service who received regular care were eligible for recruitment. In
47 2013, 8950 patients received usual care from the Salthro Thrombosis Service of which 85% had a long-
48 term indication. From June 2013 onward, a random selection of 1632 patients was approached for
49 participation in the present study using three methods, i) information and invitation by letter, ii)
50 personal invitation by specialized nurses, and iii) invitation by telephone. Patients who did not wish
51 to start with self-management were invited to participate in a parallel cohort group receiving usual
52 care (group 3), thereby providing valuable information about non-participants. Baseline
53
54
55
56
57
58
59
60

PORTALS study

characteristics of all regular patients of the Saltra Thrombosis Service also provided valuable information about non-participants.

Intervention

The intervention in group 1 and 2 consisted of a training program in combination with the use of an online self-management platform called Portavita. In group 1, patients used an e-learning that was specifically designed for the PORTALS study (Multimedia Appendix 1).

Table 1 summarizes the e-learning modules in group 1, the group training modules in group 2, and the basic training in group 3.

Table 1. Training methods in group 1, 2 and 3.

Group 1	Group 2	Group 3
<ul style="list-style-type: none"> • General education (e-learning) about anticoagulation + test • Selftesting device • Training (e-learning) selftesting + use of web portal • Three months of e-learning + selftesting 	<ul style="list-style-type: none"> • Group course with training selftesting + use of web portal • Three weeks practice at home • Group course about anti coagulation • Three months of training at home 	<ul style="list-style-type: none"> • Basic training
<ul style="list-style-type: none"> • Selftesting device 	<ul style="list-style-type: none"> • Selftesting device 	<ul style="list-style-type: none"> • Venipuncture at home or in facilities
<ul style="list-style-type: none"> • Control and quality check by nurse • Continuing self-management program + Control and quality check by nurse every six months 	<ul style="list-style-type: none"> • Control and quality check by nurse • Continuing self-management program + Control and quality check by nurse every six months 	<ul style="list-style-type: none"> • Written instructions by Thrombosis doctor

In the PORTALS study, the online self-management portal used is called Portavita (Multimedia Appendix 2). This application combines a patient portal and a healthcare provider portal. The healthcare portal leaves space for the OAT protocol, medication records, and information about complications. The Portavita Anticoagulation Self-management patient portal has become widely accepted; it provides patients with a diary tool for self-monitoring and self-dosage, education, it also allows personal notes, and healthcare professionals can send advice and notes to the patient. It implies that the patient analyzes a drop of blood using a home INR monitor. The patient can access the web-based patient portal to enter the INR and specific information for the health professional (intervention, bleeding, change in medication, vacation, etc.). Clinically validated inbuilt algorithms

PORTALS study

1
2
3 provide advice regarding the next dose and test interval. The only things needed are an internet
4 connection and a device like a PC, tablet or smartphone. When logging on (username + password) for
5 the first time to Portavita, every user was directed to the homepage. From there, users could access
6 all functionalities of the portal. The logon procedure of this portal is based on Dutch security
7 legislation and guidelines (the Dutch Personal Data Protection Act).
8
9
10

11 Data collection

12 INR values, thromboembolic events, bleedings, medication and indication were monitored and
13 registered continuously by patients in the portal and by professionals of the Saltro Thrombosis
14 Service. We measured the INR, complications and medication during a period of 6 months before
15 and 18 months after starting the intervention (i.e. 24 months in total). The data collection also
16 consisted of questionnaires (at baseline, and after each 3 x 6-month period) to measure the
17 determinants and outcomes. Patients of group 1 and 2 received these questionnaires by e-mail, and
18 patients in group 3 by e-mail or by post. In addition, the number of self-tests and use of the portal
19 were continuously registered in the portal. Data on the total population of the Saltro Thrombosis
20 Service were also collected.
21
22
23
24
25
26
27
28
29
30

31 Outcome measures and determinants

32 The primary outcome of this study was health status expressed as the INR control over time and
33 severe complications (bleedings and thromboembolic events). To summarize the INR control over
34 time, the percentage of time in therapeutic range (TTR) of INR was used, calculated with the
35 Rosendaal method [29]. TTR values were calculated for two INR ranges (INR 2-3 and INR 2-3.5)
36 because different calculations are used in Dutch and in international guidelines. TTR was measured
37 at four moments: at 6 months before intervention, and at 3 x 6-month periods (total of 18 months)
38 after starting the intervention. Serious complications were defined as those needing treatment or
39 medical evaluation. An independent thrombosis specialist was responsible for classifying serious
40 complications at the end of the trial. The total follow-up period for all these measures was 24
41 months.
42
43
44
45
46
47
48

49 Furthermore, the self-management skills of participants were evaluated. Self-management skills
50 were defined as usage of the self-management platform, reflected as the amount of login sessions.
51 Self-monitoring and self-dosage are registered within the same login session. The usage counts were
52 analyzed. The determinants were self-efficacy and socio-demographic characteristics. Self-efficacy
53 was measured at baseline using the Generalized Self-Efficacy Scale (GSES), with items scored on a
54 PORTALS study
55
56
57
58
59
60

1
2
3 four-point scale with a higher score reflecting higher self-efficacy [30]. Socio-demographic
4 characteristics were assessed by an online questionnaire addressing the following characteristics:
5 age, gender, education level, marital status, working status (labor), and quality of life (QoL), which
6 was assessed using the EuroQoL-5D (EQ-5D) and displayed at baseline. The EQ-5D is a 5-item
7 questionnaire with a higher score reflecting a higher QoL.
8
9

10 11 12 13 Sample size and statistical methods

14 To detect a relevant effect of the new implementation strategy of e-learning or group training (>5%)
15 [31] at a power 80% and $\alpha=0.05$, we calculated that a sample size of 63 patients was required per
16 group. Considering a 15% drop out, 72 (63/0.85) patients were needed per study group. Baseline
17 characteristics between the three groups were explored using Chi-square tests and Kruskal-Wallis
18 tests.
19
20
21
22

23 To investigate the effect of the different implementation methods of training versus the parallel
24 cohort group on TTR and complications, multilevel linear regression modeling (mixed models) was
25 used. First, outcomes were compared between the three groups. A second (mixed models) analysis
26 was used to compare the difference in effect between e-learning and group training (group 1 vs.
27 group 2) on TTR and complications. Analyses were adjusted for age and gender.
28
29
30
31
32

33 To examine the impact of GSES and education on the effect of the different implementation
34 methods, multiple linear regression analyses were performed with TTR at time point 3 as outcome,
35 and GSES and education as predictors. Analyses were adjusted for age and gender.
36
37
38

39 A linear regression analysis was used to analyze usage (mean number of login sessions) of the portal
40 Portavita in group 1 and 2.
41
42

43 44 45 Results

46 A total of 1632 OAT patients of the Saltro Thrombosis Service was approached to participate in the
47 study. A randomly selected group of 475 patients was informed by letter; of these, 233 responded
48 and 59 were willing to participate. Then, 692 patients were personally invited by specialized nurses
49 after thorough information about self-management; of these, 139 patients were interested to
50 participate in the study. In addition, 234 were also interested in self-management but did not want
51 to participate in the study. Trained research assistants approached 465 patients by telephone with
52 information about the possibility of self-management and the study; of these, 111 were willing to
53 participate in the study.
54
55
56
57
58
59 PORTALS study
60

participate. In addition, 52 patients signed up for self-management but were not willing to participate in the study. During the process of inviting patients for the PORTALS study, patients were asked about their reasons for not participating: the main reasons were not having a computer or internet, no digital skills, the effort of participating in a trial, and their high level of satisfaction with usual care.

Participants were included in the study only after providing written informed consent but, because some patients failed to do this, 247 participants were finally included. Of these, 110 continued to receive regular care (group 3) and 137 patients were randomly divided into group 1 and 2 using a computer program. After randomization, 63 patients were included in group 1 (e-learning) and 74 in group 2 (group training). Figure 2 summarizes the recruitment process, including the reasons for loss to follow-up.

Characteristics of the total population of the Thrombosis Service

The characteristics of all OAT patients of the Saltro Thrombosis Service in 2015 are shown in Table 2.

Table 2. Clinical characteristics of the population of the Saltro Thrombosis Service.

Total patients N	11132
Male N (%)	6009 (54.0)
Self-management N (%)	1986 (17.8)
Male self-management N (%)	1260 (63.4)
Medication	
Acenocoumarol N (%)	8360 (75.1)
Phenprocoumon N (%)	2761 (24.8)
Warfarin N (%)	11 (0.1)
Indications	
AF N (%)	7430 (66.8)
Ven thromboembolism N (%)	1673 (15.0)
Artificial valve N (%)	720 (6.5)
Other N (%)	1309 (11.8)
Severe complications	
Major bleedings N (%)	219 (2.0)
Thromboembolism N (%)	85 (0.8)

PORTALS study

Baseline characteristics of study participants

Table 3 presents the baseline characteristics of the participants: median age was 66.9 years, and median TTR was 54.7 (for INR range 2-3) and 79.1 (for INR range 2-3.5). Of these patients, 66% had an indication of AF and 77.3% used acenocoumarol as oral anticoagulation medication. No significant differences were found between the three groups for gender, TTR, indication, and marital status. Group 3 differed significantly from group 1 and 2 on age, baseline GSES and EQ-5D, use of medication, education level, and work status (Table 3).

Table 3. Baseline characteristics of patients with Oral Anticoagulation Therapy in the PORTALS study

PORTALS study

	Group 1	Group 2	Group 3	p-value	Total
N	63	74	110		247
Age in years* [IQR]	65.0 ^a [56.2-67.7]	65.8 ^a [56.4-70.4]	69.6 ^b [64.0-74.9]	0.00**	66.9 [59.5-72.7]
Males N (%)	47 (74.6)	52 (70.3)	81 (73.6)	0.826	180 (72.9)
TTR INR range 2-3 (%)* [IQR]	50.2 [39.1-67.1]	52.9 [39.0-68.6]	57.4 [40.1-75.1]	0.159	54.7 [39.8-70.7]
TTR INR range 2-3.5 (%)* [IQR]	76.3 [67.0-86.0]	77.1 [64.1-85.3]	85.6 [72.0-93.5]	0.159	79.1 [68.2-88.8]
GSES* [IQR]	3.5 ^a [3.1-3.8]	3.3 ^{a,b} [3.0-3.7]	3.1 ^b [2.9-3.5]	0.001**	3.3 [3.0-3.7]
EQ5D* [IQR]	1.0 ^a [0.81-1.0]	0.84 ^{a,b} [0.78-1.0]	0.84 ^b [0.78-1.0]	0.036**	0.84 [0.81-1.0]
Indication					
AF N (%)	42 (66.7)	44 (59.5)	77 (70.0)	0.215	163 (66)
Ven thromboembolism N (%)	13 (20.6)	18 (24.3)	11 (10.0)		42 (17)
Artificial valve N (%)	2 (3.2)	3 (4.1)	4 (3.6)		9 (3.6)
Other N (%)	6 (9.5)	9 (12.2)	18 (16.4)		33 (13.4)
Medication					
Acenocoumarol N (%)	51 (81) ^a	64 (86.5) ^a	76 (69.1) ^b	0.004**	191 (77.3)
Phenprocoumon N (%)	10 (15.9) ^a	10 (13.5) ^a	34 (30.9) ^b		54 (21.9)
Warfarin N (%)	2 (3.2) ^a	0 (0) ^a	0 (0) ^a		2 (0.8)
Education level					
Low N (%)	7 (12.1) ^a	13 (19.1) ^a	33 (35.9) ^b	0.00**	53 (24.3)
Medium N (%)	24 (41.4) ^a	32 (47.1) ^a	46 (50.0) ^a		102 (46.8)
High N (%)	27 (46.6) ^a	23 (33.8) ^b	13 (14.1) ^c		63 (28.9)
Marital status					
Married N (%)	49 (84.5)	50 (73.5)	73 (79.3)	0.280	172 (78.9)
Widow N (%)	1 (1.7)	6 (8.8)	4 (4.3)		11 (5.0)
Divorced N (%)	1 (1.7)	6 (8.8)	4 (4.3)		11 (5.0)
Single N (%)	7 (12.1)	6 (8.8)	11 (12.0)		24 (11.0)
Labour					
No paid work N (%)	28 (48.3) ^a	29 (42.6) ^a	39 (42.4) ^a	0.043**	96 (44.0)
Paid work N (%)	19 (32.8) ^a	20 (29.4) ^a	14 (15.2) ^b		53 (24.3)
Household N (%)	8 (13.8) ^a	11 (16.2) ^a	23 (25.0) ^a		42 (19.3)
Incapacitated N (%)	3 (5.2) ^a	8 (11.8) ^a	16 (17.4) ^a		27 (12.4)

*Values are medians and corresponding Interquartile Ranges [IQR]

** Between-group differences (P < 0.05) are indicated by **

Each superscript (a,b,c) letter denotes a subset of sample categories which do not differ significantly from each other at the 0.05 level.

TTR is the therapeutic international normalized ratio (INR) range, GSES is the General Self-efficacy Scale, EQ5D EuroQol five dimensions questionnaire is a standardized instrument for use as a measure of health outcome.

N Missing questionnaires: GSES 29, EQ5D 32, indication 0, medication 0, education 29, marital status 29, labour 29.

Health status before and after intervention

Figure 3A shows the TTR values using the INR 2-3 in the three groups, 6 months before the intervention and in the 3 x 6-month periods after the intervention; the TTR values using the INR 2-3.5 are presented in Figure 3B (Appendix 3).

PORTALS study

1
2
3 Analysis of the three groups showed no significant difference in TTR values over time ($p=0.520$),
4 between the groups ($p=0.398$), or between the groups over time ($p=0.418$).
5
6

7
8 Analysis of the two self-management groups showed no significant differences in TTR values
9 between the four time periods ($p=0.614$). Also, no significant differences in TTR were found between
10 group 1 and 2 ($p=0.460$) or between these two groups over time ($p=0.263$).
11
12

13
14 The sensitivity analyses showed that using an INR of 2-3.5, instead of 2-3, had no marked effect on
15 the results, although a significant time effect was found. Results are presented in figure 3B in
16 Appendix 3.
17
18
19

20
21 During the 18-month period after the intervention, across all three groups, a total of 3 severe
22 complications occurred ($3/247=1.2\%$): i.e. two muscular bleedings in the e-learning group
23 ($2/63=3.2\%$) and one cerebrovascular accident among patients receiving group training ($1/74=1.4\%$);
24 no complications occurred in the usual care group.
25
26
27

28 29 Educational level and GSES

30
31 Educational level was not associated with the TTR in the last 6 months ($p=0.107$); education level did
32 not modify the effect of the different implementation methods on TTR ($p=0.161$).
33

34 No association was found between the GSES and TTR in the last 6 months ($p=0.717$); GSES did not
35 modify the effect of the different implementations methods on TTR ($p=0.174$).
36
37
38

39 Usage of the platform

40
41 Figure 4 presents the usage by patients in group 1 and 2 (using the logfiles of the Portavita platform)
42 during the 18 months after start of the intervention. Patients logged on to the platform to register
43 their INR; some also used it to establish their medication dosage or to communicate with healthcare
44 professionals of the Thrombosis Service. There was no significant difference between group 1 and 2
45 in usage of the platform during the three time periods (0-6 months $p=0.571$; 6-12 months $p=0.866$;
46 12-18 months $p=0.260$).
47
48
49
50
51
52

53 Discussion

54
55 In the present study, no differences were found in health status and usage of the platform between
56 anticoagulation self-management patients trained by e-learning and by group training. Moreover,
57 PORTALS study
58
59
60

1
2
3 the clinical results for self-management patients were similar to those of patients receiving regular
4 care. Therefore, we conclude that, with adequate training through e-learning or group training, self-
5 management is safe and reliable for a selected proportion of motivated patients receiving OAT. The
6 PORTALS study provides valuable information on different implementation methods of OAT self-
7 management, including eHealth.
8
9

10 11 12 13 Strengths and limitations

14 This PORTALS study has several strengths. First, the study investigates the effect of different
15 education programs in a situation as close to 'real life' as possible, integrated in a self-management
16 program including eHealth, on clinical outcomes and self-management skills. The study also adds
17 evidence to the existing body of knowledge on implementation of eHealth; this is important because
18 local political/financial factors have a major impact on successful integration of eHealth in daily
19 practice and because self-management is important for patients who will use VKAs and NOACs in the
20 future [32].
21
22
23
24
25
26

27 This study also has limitations. First, a randomized controlled trial (RCT) was not feasible in our
28 setting of an implementation design in a real-life healthcare system with patients who have differing
29 demands. Instead, an observational study was considered the best option for our context, i.e.
30 patients cannot be denied or forced to start with self-management. Furthermore, self-management
31 skills imply behavioral changes. However, behavioral changes require time, whereas the study period
32 was restricted to 18 months. This study also has limitations typically associated with eHealth trials.
33 For example, as patients were free to volunteer, bias might have occurred in our study groups. Users
34 were self-selected and were, presumably, motivated to use the education program (including the
35 web-based platform) as would be expected in a real-life setting. Of the 1632 invited OAT patients,
36 247 patients (15%) were willing to participate and provided informed consent. However, only 137
37 patients (8.4% of invited patients) wanted to participate in the self-management groups and were
38 randomized; other studies have a similar low recruitment rate for self-management trials [33]. This
39 phenomenon might have affected the measurability of differences and might also reduce differences
40 between the groups.
41
42
43
44
45
46
47
48
49
50

51 The total population of the Thrombosis Service showed a lower percentage of men than the
52 participants of the present study, although the distribution of indications/medication was similar. In
53 the total population, the percentage of severe complications was low (bleedings 2%,
54
55
56
57
58
59
60

PORTALS study

1
2
3 thromboembolism 0.8%); during our study period the percentage of complications was also low
4 (group 1=1.4%; group 2=1.2%; group 3=0%), indicating a high quality of thrombosis care.
5
6

7
8 During the process of inviting patients for the PORTALS study, we asked their reasons for not
9 participating (main reasons were: not having a computer/internet, no digital skills, the effort of
10 participating, and their high level of satisfaction with usual care). The group with usual care differed
11 significantly from the self-management groups on several baseline characteristics: i.e. patients in
12 usual care were older, had a lower education level, and fewer of them had paid work. Also, they had
13 a lower GSES and EQ5D, and made less use of acenocoumarol. Patients in the total population of the
14 Thrombosis Service, and in the usual care group, might have different wishes and expectations
15 towards care than patients that chose for a self-management program; i.e. self-management
16 programs are suitable for patients that are highly motivated and have skills for self-management
17 tasks.
18
19

20
21 Finally, to measure a significant difference in health status, 72 patients were needed in each group.
22 Although these numbers were not entirely met in group 1 (e-learning), analysis of the groups should
23 be sufficiently powered to detect relevant differences. In addition, the high number of INR data
24 points collected before and after the intervention has a substantial impact on the strength of the
25 design and the multilevel linear analysis.
26
27

28
29 Due to these limitations, caution is required when generalizing our results to general practice.
30 However, the practical applicability of our results for other specialized OAT centers is positive, i.e. the
31 study provides practical insight into successful implementation of self-management programs
32 consisting of high-quality training and usage of a patient platform.
33
34

35 Interpretation of findings

36
37 No overall significant differences in health status were found between the three groups. Therapeutic
38 INR control was good in all groups; in the last 6 months of the intervention period, all groups spent
39 around 58% of time within the narrow therapeutic range 2-3 and 83% of time within the therapeutic
40 range 2-3.5; this indicates high quality and is comparable to other studies [33] [34]. It is reported that
41 any management model should demonstrate anticoagulation control levels around 60% for TTR of
42 INR range 2-3 to be considered safe [34] [35] [36]. In studies conducted outside specialized care
43 facilities in several different regions, INR readings ranged from 40-70% of the time within target
44 range using an existing care delivery system [13]. In the present study, the quality of OAT
45
46

47
48
49
50
51
52
53
54
55
56
57
58
59
60
PORTALS study

1
2
3 management can be considered high in all groups. Since the routine OAT management is already of
4 high quality, further improvement of TTR is difficult to achieve. Furthermore, the national guidelines
5 for the INR range changed during the last 6 months of our PORTALS study; this had a negative impact
6 on the TTR during our last measurement period. Complication rates also compared favorably with
7 international data; our overall adverse event rate was low compared to other studies, including
8 studies on NOACs [37] [38] [39].
9
10

11
12
13
14 Self-efficacy and educational level of users had no impact on health status for the different
15 implementation methods. The construct of perceived self-efficacy reflects an optimistic self-belief
16 [30]; a correlation can be understood based on the belief that one can perform a novel or difficult
17 task, or cope with adversity (indicating a higher self-efficacy). In the present study, self-efficacy was
18 comparable to that in a healthy Dutch population [40] [41].
19
20
21
22
23

24 Usage of the Portavita portal remained high during the 18-month study period and attrition was low.
25 Usually, the 'law of attrition' (the phenomenon of participants stopping usage) is a common finding
26 in eHealth evaluations and an important challenge in the evaluation of eHealth applications [42]. The
27 practical value of the Portavita portal is very high for patients, because of the functionalities of self-
28 monitoring, self-dosage and digital advice from professional healthcare providers. Because patients
29 use the self-management program, regular visits to medical facilities are unnecessary. Patients can
30 manage their anticoagulation in their own time and in their own chosen place. Thus, using the self-
31 management program gives them (extra) freedom; this might be a strong motivating factor for using
32 the program. Also, the training programs were sound and sustainable during the entire study period,
33 probably stimulating patients to persevere with their self-management program. Moreover, e-
34 learning and group training led to the same usage and, therefore, the same self-management skills.
35 Therefore, we conclude that our e-learning and group training provide a good start for OAT patients
36 that voluntarily start with a self-management program including eHealth.
37
38
39
40
41
42
43
44
45

46 Self-management programs with eHealth technologies for chronic conditions can be used to enhance
47 self-management and revise the Chronic Care Model; patients who actively participate in their care
48 achieve valuable and sustained improvement in wellbeing [43] [44]. In many eHealth studies, use of a
49 Personal Health Record or self-management platform can promote an informed/activated patient
50 and augment the Chronic Care Model for self-management support and productive interactions;
51 even though a direct dosage-effect relation (usually analyzed in a classical RCT) is not common in
52 eHealth [45]. Self-management programs with good training and practical eHealth platforms have
53
54
55
56
57
58

59 PORTALS study
60

1
2
3 the potential to make chronic care personalized in a blended care model; every patient needs a
4 different approach for an optimal health status. Healthcare providers need to embrace a different
5 role and release tight protocols [46]. Individual patients have different expectations and wishes,
6 which should be a topic of conversation with each patient.
7
8
9

10
11 More studies are needed (preferably with larger sample groups, and including non-users) to gain
12 more insight into the preferences of various patient groups, as well as the related costs.
13

14 The substantial workload generated by integrating a web-based platform in an OAT self-management
15 program emphasizes the importance of piloting and assessing workforce implications for OAT
16 management centers. The present results provide additional insight into the organizational aspects
17 of the implementation of education programs into a self-management program with a platform,
18 including the need to educate and coach patients in the use of web-based platforms.
19
20
21
22

23 Conclusion

24
25 Our main finding is that there were no differences in health status and usage of a supporting eHealth
26 platform between anticoagulation self-management patients trained by e-learning and by group
27 training. Moreover, we found that clinical results for self-management patients are comparable to
28 those of patients receiving usual care. We conclude that with appropriate and sound training through
29 e-learning or group training, self-management is safe and reliable for a selected proportion of
30 motivated patients receiving oral anticoagulation treatment. The PORTALS study provides valuable
31 information on different implementation methods of oral anticoagulation self-management,
32 including eHealth.
33
34
35
36
37
38
39
40
41

42 Acknowledgments

43
44 The authors wish to thank all patients and caregivers within the Saltrø Thrombosis Service Centre.
45 The authors thank Pim Assendelft for his valuable contribution to the design and Joke van der Feest,
46 Nynke Wiersma, Carola Guse and Sandra Claassen for their research assistance. The authors also
47 thank Nan van Geloven for reviewing the statistical analysis.
48
49
50

51 Data sharing

52
53 Data will be made available for sharing where available and appropriate.
54
55
56
57
58
59
60

PORTALS study

Transparency declaration

The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

All authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Ethics and consent to participate

This study is conducted according to the principles of the Declaration of Helsinki (version 59, 2008) and in accordance with the Medical Research Involving Human Subjects Act (WMO). Participants were only included in the study after written informed consent was received. The Medical Ethics Committee of the LUMC approved this study (Reference No. P12.278).

Competing interests

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Funding

This work was supported by the Foundation Care Within Reach (in Dutch: Stichting Zorg Binnen Bereik).

Author's contributions

ET is the principle investigator and contributed to all aspects of the research. NV assisted on all aspects. MK assisted on the statistical analysis and is responsible for revising the manuscript several times. LH is responsible for revising the manuscript several times. IT is responsible for the acquisition of data and revising the manuscript several times. MN is responsible for revising the manuscript. NC is responsible for the concept, design, and for revising the manuscript. All authors read and approved the final manuscript.

PORTALS study

References

1. Streiff MB, Carolan HT, Hobson DB, Kraus PS, Holzmueller CG, Demski R, Lau BD, Biscup-Horn P, Pronovost PJ, Haut ER. Lessons from the Johns Hopkins Multi-Disciplinary Venous Thromboembolism (VTE) Prevention Collaborative. *BMJ*. 2012 Jun 19;344:e3935. DOI: 10.1136/bmj.e3935.
2. CBO Richtlijn Diagnostiek, preventie en behandeling van Veneuze trombo-embolie en Secundaire Preventie Arteriele trombose 2009 [CBO Diagnostics Guidelines, prevention and treatment of venous thromboembolism and secondary prevention of arterial thrombosis 2009].
3. Schnabel RB et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet*, Volume 386, Issue 9989, 154 – 162. July 2015. DOI: [http://dx.doi.org/10.1016/S0140-6736\(14\)61774-8](http://dx.doi.org/10.1016/S0140-6736(14)61774-8).
4. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek ME, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GYH. Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2_suppl):e531S-e575S. doi:10.1378/chest.11-2304.
5. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP. Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis. *Circulation* May 22, 2001, Volume 103, Issue 20. doi: <https://doi.org/10.1161/01.CIR.103.20.2453>.
6. Torn M, Bollen WLE, Meer van der FJM, Wall van der EE, Rosendaal FR. Risks of Oral Anticoagulant Therapy With Increasing Age. *Arch Intern Med*. 2005;165:1527-1532. doi:10.1001/archinte.165.13.1527.
7. Heneghan C, Ward A, Perera R, Self-Monitoring Trialist Collaboration, Bankhead C, Fuller A, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. *Lancet* 2012 Jan 28;379(9813):322-334 doi: 10.1016/S0140-6736(11)61294-4.
8. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. *N Engl J Med* 2003;349:1019-26. DOI: 10.1056/NEJMoa022913.
9. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. *Blood* 2014 124:2450-2458; doi: <https://doi.org/10.1182/blood-2014-07-590323>

PORTALS study

- 1
2
3 10. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandembroucke JP, Briet E.
4 Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart Valves. *N Engl J Med* 1995;
5 333:11-17. July 6, 1995. DOI: 10.1056/NEJM199507063330103.
6
7 11. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI,
8 Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, Nguyen P, Demers C, Kahn SR, Kassis J,
9 Rodger M, Hambleton J, Gent M. Comparison of Low-Intensity Warfarin Therapy
10 with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous
11 Thromboembolism. *N Engl J Med* 349;7. DOI: 10.1056/NEJMoa035422.
12
13 12. Kimmel SE, Chen Z, Price M, Gross R. The Influence of Patient Adherence on Anticoagulation
14 Control With Warfarin; Results From the International Normalized Ratio Adherence and Genetics (IN-
15 RANGE) Study. *Arch Intern Med*. 2007;167(3):229-235. DOI: 10.1001/archinte.167.3.229.
16
17 13. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC,
18 Breithard G, Hankey JG, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KAA. Impact of Global
19 Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the
20 ROCKET AF Clinical Trial. *J Am Heart Assoc*. 2013;2:e000067 doi: 10.1161/JAHA.112.000067.
21
22 14. McLean S, Protti D, Sheikh A. Telehealthcare for long-term conditions. *BMJ* 2011;342:d120. doi:
23 10.1136/bmj.d120.
24
25 15. Gadisseur APA, Kaptein AA, Breukink-Engbers WGM, van der Meer FJM, Rosendaal FR. Patient
26 self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics:
27 positive effects on quality of life. *J Thromb Haemost* 2004 Apr;2(4):584-591. DOI: 10.1111/j.1538-
28 7836.2004.00659.x.
29
30 16. McCahon D, Murray ET, Murray K, Holder RL, Fitzmaurice DA. Does self-management of oral
31 anticoagulation therapy improve quality of life and anxiety? *Fam Pract* 2011 Apr;28(2):134-140.
32 DOI: 10.1093/fampra/cm089.
33
34 17. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, Alonso-Coello P,
35 Fitzmaurice D, Mahtani KR, Onakpoya IJ. Self-monitoring and self-management of oral
36 anticoagulation. *Cochrane Heart Group* 2016. DOI: 10.1002/14651858.CD003839.pub3.
37
38 18. Newman S, Steed L, Mulligan K. Self-management interventions for chronic illness. *Lancet* 2004;
39 364: 1523–37. DOI: 10.1016/S0140-6736(04)17277-2.
40
41 19. Bouillon K, Bertrand M, Maura G, Blotière PO, Ricordeau P, Zureik M. Risk of bleeding and arterial
42 thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K
43 antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-
44 cohort study. *Lancet Haematol* 2015 Apr;2(4):e150-9. doi: 10.1016/S2352-3026(15)00027-7.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PORTALS study

- 1
2
3 20. Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, et al. Safety and effectiveness of
4 oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein
5 thrombosis (XALIA): An international, prospective, non-interventional study. *Lancet Haematol*
6 2016;3:e12-21 . doi: 10.1016/S2352-3026(15)00257-4.
7
8
9 21. Lin L, Lim WS, Zhou HJ, Khoo AL, Tan KT, Chew AP, et al. Clinical and safety outcomes of oral anti-
10 thrombotics for stroke prevention in atrial fibrillation: A systematic review and network meta-
11 analysis. *J Am Med Dir Assoc* 2015;16:1103.e1-19. doi: 10.1016/j.jamda.2015.09.008.
12
13 22. Lorig K, Ritter P, Stewart A, Sobel D, Brown B, Bandura A, Gonzalez V, Laurent D, Holman H.
14 Chronic Disease Self-Management Program. 2-Year Health Status and Health Care Utilization
15 Outcomes. *Med Care*. 2001 Nov;39(11):1217-23. PMID: 11606875.
16
17 23. Mishali M, Omer H, Heymann A. The importance of measuring self-efficacy in patients with
18 diabetes. *Fam Pract*. 2011 Feb;28(1):82-7. doi: 10.1093/fampra/cm086.
19
20 24. Simpson E, Jones MC. An exploration of self-efficacy and self-management in COPD patients. *Br J*
21 *Nurs*. 2013 Oct 24-Nov 13;22(19):1105-9. DOI: 10.12968/bjon.2013.22.19.1105
22
23 25. Rajati F, Sadeghi M, Feizi A, Sharifirad G, Hasandokht T, Mostafavi F. Self-efficacy strategies to
24 improve exercise in patients with heart failure: A systematic review. *ARYA Atheroscler*. 2014
25 Nov;10(6):319-33. PMID: 25815022.
26
27 26. Kontos E, Blake KD, Chou WYS, Prestin A. Predictors of eHealth Usage: Insights on The Digital
28 Divide From the Health Information National Trends Survey 2012. *J Med Internet Res*
29 2014;16(7):e172. doi:10.2196/jmir.3117.
30
31 27. van Bokhoven MA, Kok G, van der Weijden T. Designing a quality improvement intervention: a
32 systematic approach. *Qual Saf Health Care*. 2003;12:215–20. PMID: 12792013
33
34 28. Talboom EPWA, Verdijk NA, Talboom IJSH, Harmans LM, Numans ME, Chavannes NH. PORTALS:
35 design of an innovative approach to anticoagulation management through eHealth. *BMC Health*
36 *Services Research* (2017) 17:213 DOI 10.1186/s12913-017-2142-2
37
38 29. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal
39 intensity of oral anticoagulant therapy. *Thromb Haemost*. 1993;69(3):236–9. PMID: 8470047
40
41 30. Scholz U, Gutiérrez-Doña B, Sud S, Schwarzer R. Is general self-efficacy a universal construct?
42 Psychometric findings from 25 countries. *Eur J Psychol Assess*. 2002;18:242–51.
43
44 31. Heneghan C, Ward A, Perera R et al. Self-monitoring of oral anticoagulation: systematic review
45 and meta-analysis of individual patient data. *Lancet*. 2012 Jan 28;379(9813):322-34. DOI:
46 10.1016/S0140-6736(11)61294-4
47
48 32. Nijland N. Thesis: Grounding eHealth. Towards an holistic framework for sustainable eHealth
49 technologies. University of Twente; 2011. ISBN: 9789036531337
50
51
52
53
54
55
56
57
58
59 PORTALS study
60

- 1
2
3 33. Gadisseur AP, Breukink-Engbers WG, Meer van der FJ, Besselaar van den AM, Sturk A, Rosendaal
4 FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and
5 management by specialized anticoagulation clinics in the Netherlands: a randomised clinical trial.
6 Arch Int Med 2003;163:2639-46. DOI: 10.1001/archinte.163.21.2639
7
8 34. Menéndez-Jándula B, Souto JC, Oliver A, Montserat I, Quintana M, Gich I, et al. Comparing self-
9 management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern
10 Med 2005;142:1-10. PMID: 15630104.
11
12 35. Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S, et al. Self-management
13 of oral anticoagulation: randomised trial. BMJ 2005 Nov 5;331(7524):1057 doi:
14 10.1136/bmj.38618.580903.AE.
15
16 36. Ryan F, Byrne S, O'Shea S. Randomized controlled trial of supervised patient self-testing of
17 warfarin therapy using an internet-based expert system. J Thromb Haemost 2009 Aug;7(8):1284-
18 1290. doi: 10.1111/j.1538-7836.2009.03497.x.
19
20 37. Rein van N, Lijfering WM, Bos MHA, Herruer MH, Vermaas HW, Meer van der FJM, Reitsma PH.
21 Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for
22 Major Bleeding during Treatment with Vitamin K Antagonists. PLoS ONE 11(12): e0164485.
23 doi:10.1371/journal.pone.0164485.
24
25 38. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage:
26 results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151(3):713-719. DOI:
27 10.1016/j.ahj.2005.04.017.
28
29 39. Chai-Adisaksotha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in
30 patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood.
31 2014;124(15):2450-2458. DOI 10.1182/blood-2014-07- 590323.
32
33 40. Schwarzer R. Self-efficacy: Thought Control of Action. Hemisphere Publishing Corporation; 1992.
34 ISBN: 9781560322696.
35
36 41. Luszczynska A, Gutiérrez-Doña B, Schwarzer R. General self-efficacy in various domains of human
37 functioning: Evidence from five countries. Int J Psychol 2005; 40 (2), 80–89.
38 doi: 10.1080/00207590444000041.
39
40 42. Eysenbach G. The Law of Attrition. J Med Internet Res 2005;7(1):e11. PMID: 15829473
41
42 43. Siminerio LM. The role of technology and the chronic care model. J Diabetes Sci Technol 2010
43 Mar;4(2):470-475. DOI: 10.1177/193229681000400229.
44
45 44. Stelfox M, Chaney B, Barry AE, Chavarria E, Tennant B, Walsh-Childers K, et al. Web 2.0 chronic
46 disease self-management for older adults: a systematic review. J Med Internet Res 2013;15(2):e35.
47 doi: 10.2196/jmir.2439.
48
49 PORTALS study
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

45. Archer N, Fevrier-Thomas U, Lokker C, McKibbin KA, Straus SE. Personal health records: a scoping review. *J Am Med Inform Assoc* 2011;18(4):515-522. doi: 10.1136/amiajnl-2011-000105.

46. Sun X, Guyatt GH. Interventions to enhance self-management support. *BMJ* 2013;346:f3949. doi: <https://doi.org/10.1136/bmj.f3949>.

For peer review only

PORTALS study

Saltro Thrombosis Service Centre			
	Self-Management		Usual Care
Patients	Group 1	Group 2	Group 3
	#72	#72	#72
Instruction	E-Learning <ul style="list-style-type: none"> disease-specific knowledge self-testing skills use of the web-portal (voluntary) self-adjustment of medication 	Group Course <ul style="list-style-type: none"> disease-specific knowledge self-testing skills use of the web-portal (voluntary) self-adjustment of medication 	Basic Short Training
Platform	Self-management	Self-management	-

Figure 1. Overview of the study design: details of groups 1, 2 and 3

BMJ Open: first published as 10.1136/bmjopen-2017-017909 on 27 September 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Flowchart of the PORTALS study.

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3A




Figure 3A. Health status based on time in therapeutic (TTR) (for INR range 2-3) for the three groups.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Usage of participants in group 1 and group 2 after start of the intervention.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Appendix 1: E-learning anticoagulation

review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The screenshot displays the homepage of the Saltro self-management web portal. The page is titled 'Homepage from Selfmanagement, S.' and includes a navigation menu on the left with options like 'Home page', 'Enter logbook', and 'Enter dose'. The main content area is divided into several sections:


- Personal data:** Patient number SELF01992765.
- Most recent dosing schedule (provisional):** Dosing period 28-03-2017 until 17-04-2017, Anticoagulation medication Acenocoumarol 1 mg, Dosing schedule created on 28-03-2017 by Selfmanagement, S., Dose according to step 25, Measurement frequency 21 days, Tolerance 3 days.
- Important data:** Dosing schedule based on INR 3,6 measured on Tue. 28-03-2017 at 06:46, Next Thrombosis Service check-up Tue. 17-01-2017 at 09:00, Next blood sampling date Tue. 18-04-2017.
- Calendar view:** A table showing the dosing schedule for weeks 13, 14, 15, and 16. The table has columns for days of the week and corresponding dates and doses.
- Print dosing schedule** and **Print holiday letter** buttons.
- Messages:** A table showing new messages from Trombosedienst Demo.

	wk. 13	wk. 14	wk. 15	wk. 16
Mon.		3 Apr. 2	10 Apr. 2	17 Apr. 2
Tue.	28 Mar. 1	4 Apr. 2	11 Apr. 1	18 Apr. 2
Wed.	29 Mar. 2	5 Apr. 2	12 Apr. 2	19 Apr. 2
Thu.	30 Mar. 2	6 Apr. 1	13 Apr. 2	20 Apr. 1
Fri.	31 Mar. 2	7 Apr. 2	14 Apr. 2	
Sat.	1 Apr. 1	8 Apr. 2	15 Apr. 1	
Sun.	2 Apr. 2	9 Apr. 2	16 Apr. 2	

Subject (read message)	New messages from	Date	Time
Er is een opmerking bij uw doseschema toegevoegd of gewijzigd	Trombosedienst Demo	19-01-2017	12:48
test	Trombosedienst Demo	12-01-2017	16:18

Appendix 2: Patients' self-management web portal homepage

3B



Appendix 3: Health status based on time in therapeutic (TTR) (for INR range 2-3.5) for the three groups. Figure 3B shows TTR values using the INR 2-3.5 in the three groups, 6 months before the intervention and in the 3 x 6-month periods after the intervention. Analysis of the three groups showed that the TTR values differed significantly over time ($p=0.017$). No significant differences were found in TTR between the groups ($p=0.163$) or between the groups over time ($p=0.545$).

Analysis of the two self-management groups showed significant differences in the TTR values between the four time periods (i.e. pre- and postintervention) ($p=0.008$). There were no significant differences in TTR between group 1 and 2 ($p=0.721$) or between the groups over time ($p=0.825$).

Equivalent health status for e-learning, group training self-management or usual care in oral anticoagulation patients: a parallel cohort design in the PORTALS Study

STROBE statement, checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract		
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract – Page 1 (b) Provide in the abstract an informative and balanced summary of what was done and what was found – Page 2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported – Page 3 (Introduction)
Objectives	3	State specific objectives, including any prespecified hypotheses – Page 4 (Introduction)
Methods		
Study design	4	Present key elements of study design early in the paper – Page 5/6 (Study design) + figure 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection – Page 5 (Study design) + reference 28
Participants	6	(a) <i>Cohort study?</i> Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up – Page 6 (Participants) + reference 28
		(b) <i>Cohort study?</i> For matched studies, give matching criteria and number of exposed and unexposed Participants were not matched + figure 1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give

	Item No	Recommendation
		diagnostic criteria, if applicable – Page 8/9 (Outcome measures and determinants)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). – Page 8/9 (Outcome measures and determinants) Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias – Page 9 (Sample size and statistical methods)
Study size	10	Explain how the study size was arrived at – Page 9 (Sample size and statistical methods)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why – Page 8/9 (Outcome measures and determinants)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding – Page 9 (Sample size and statistical methods)
		(b) Describe any methods used to examine subgroups and interactions – Page 9 (Sample size and statistical methods)
		(c) Explain how missing data were addressed – Page 9 (Sample size and statistical methods)
		(d) Cohort study? If applicable, explain how loss to follow-up was addressed – Page 9 (Sample size and statistical methods)
		(e) Describe any sensitivity analyses Not applicable.
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study? eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed – Page 9/10 (Results)
		(b) Give reasons for non-participation at each stage – Page 10/11 (Baseline characteristics of study participants)
		(c) Consider use of a flow diagram Figure 2.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders – Page 10/11 (Baseline characteristics of study participants)

	Item No	Recommendation
		(b) Indicate number of participants with missing data for each variable of interest – Page 10/11 (Baseline characteristics of study participants) + Table 3
		(c) Cohort study? Summarise follow-up time (eg average and total amount) – Page 8/9 (Outcome measures and determinants)
Outcome data	15*	Cohort study? Report numbers of outcome events or summary measures over time – Page 12/13 (Usage of the platform)
Main results	16	(a) Report the numbers of individuals at each stage of the study? eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed – Page 9/10 (Results)
		(b) Give reasons for non-participation at each stage – Page 9/10 (Results)
		(c) Consider use of a flow diagram Figure 2.
Other analyses	17	Report other analyses done? eg analyses of subgroups and interactions, and sensitivity analyses Page 12 (Health status before and after intervention/Educational level and GSES)
Discussion		
Key results	18	Summarise key results with reference to study objectives – Page 13 (Discussion)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias – Page 13/14 (Strengths and limitations)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence – Page 14/15 (Interpretation of findings)
Generalisability	21	Discuss the generalisability (external validity) of the study results – Page 16 (Interpretation of findings)
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based – Page 17 (Funding)

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross sectional studies.

1
2
3 The STROBE checklist is best used in conjunction with the explanation and elaboration article.¹⁸⁻²⁰ This
4 article and separate versions of the checklist for cohort, case-control, and cross sectional studies are
5 available at www.strobe-statement.org.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

Equivalent therapeutic control for oral anticoagulation patients with e-learning, group training self-management or usual care: a parallel cohort design in Dutch primary care

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017909.R1
Article Type:	Research
Date Submitted by the Author:	31-Jul-2017
Complete List of Authors:	Talboom-Kamp, Esther; LUMC, Public Health and Primary Care Department; SALTRO Diagnostic Centre, Verdijk, Noortje; LUMC, Public Health and Primary Care Department; SALTRO Diagnostic Centre, Kasteleyn, Marise; LUMC, Public Health and Primary Care Department Harmans, Lara; SALTRO Diagnostic Centre, Talboom, Irvin; Zorgdraad Foundation Numans, Mattijs; LUMC, Public Health and Primary Care Department Chavannes, Niels; LUMC, Public Health and Primary Care Department
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Health informatics, Medical education and training, General practice / Family practice
Keywords:	self-efficacy, eHealth, TTR, self-management, thrombosis, oral anticoagulation

SCHOLARONE™
Manuscripts

Equivalent therapeutic control for oral anticoagulation patients with e-learning, group training self-management or usual care: a parallel cohort design in Dutch primary care

EPWA Talboom-Kamp MD MBA^{1,2}, NA Verdijk MSc PhD^{1,2}, MJ Kasteleyn MSc PhD¹, LM Harmans MSc², IJSH Talboom³, ME Numans MD PhD¹, NH Chavannes MD PhD¹

¹Leiden University Medical Centre, Public Health and Primary Care Department
P.O. Box 9600, 2300 RC Leiden, the Netherlands

²Saltro Diagnostic Centre
Mississippidreef 83, 3565 CE Utrecht, the Netherlands

³Zorgdraad Foundation
Wijnand van Arnhemweg 54, 6862XN Oosterbeek, the Netherlands

Corresponding author

EPWA (Esther) Talboom-Kamp MD MBA
Saltro Diagnostic Centre
Mississippidreef 83
3565 CE Utrecht
The Netherlands
Telephone: +31-30-2361170
Fax: +31-30-2361172
E-mail: e.talboom@saltro.nl

1
2
3 Abstract

4 **Objectives** To analyze the effect on therapeutic control and self-management skills of the
5 implementation of self-management programs, including eHealth by e-learning versus group
6 training.
7
8

9
10
11 **Setting** Primary Care Thrombosis Service Center.
12

13
14 **Participants** Of the 247 OAT patients, 63 started self-management by e-learning, 74 self-
15 management by group training, and 110 received usual care.
16

17
18 **Intervention and methods** Parallel cohort design with two randomized self-management groups (e-
19 learning and group training) and a group receiving usual care. The effect of implementation of self-
20 management on time in therapeutic range (TTR) was analyzed with multilevel linear regression
21 modeling. Usage of a supporting eHealth platform and the impact on self-efficacy (Generalized Self-
22 Efficacy Scale; GSES) and education level were analyzed with linear regression analysis. After
23 intervention, TTR was measured in 3 time periods of 6 months.
24
25
26
27

28
29 **Main outcome measures** i) TTR, severe complications ii) usage of an eHealth platform iii) GSES,
30 education level.
31
32

33
34 **Results** Analysis showed no significant differences in TTR between the three time periods ($p=0.520$),
35 the three groups ($p=0.460$) or the groups over time ($p=0.263$). Comparison of e-learning and group
36 training showed no significant differences in TTR between the time periods ($p=0.614$), the groups
37 ($p=0.460$) or the groups over time ($p=0.263$). No association was found between GSES and TTR
38 ($p=0.717$), or education level and TTR ($p=0.107$). No significant difference was found between the
39 self-management groups in usage of the platform (0-6 months $p=0.571$; 6-12 months $p=0.866$; 12-18
40 months $p=0.260$). The percentage of complications was low in all groups (3.2%; 1.4%; 0%).
41
42
43
44
45
46
47

48 **Conclusions** No differences were found between OAT patients trained by e-learning or by a group
49 course regarding therapeutic control (TTR) and usage of a supporting eHealth platform. The TTR was
50 similar in self-management and regular care patients. With adequate e-learning or group training,
51 self-management is safe and reliable for a selected proportion of motivated VKA patients.
52
53
54

55
56
57 Trial Registration – NTR3947
58
59
60

1
2
3
4
5 **Keywords** – oral anticoagulation; TTR; eHealth; self-management; self-efficacy; e-learning;
6 thrombosis; self-monitoring.
7
8
9

10 Article summary

11 Strengths and limitations of this study

- 12 • This study provides practical insight into successful implementation of self-management
13 programs consisting of high-quality training and usage of a patient platform;
 - 14 • The study findings add important evidence to the existing body of knowledge on
15 implementation of eHealth;
 - 16 • The needed number of participants was not entirely met in one of the groups;
 - 17 • Behavioral changes require time, whereas the study period was restricted to 18 months;
 - 18 • Patients were free to volunteer, which might have caused bias in our study groups.
- 19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Venous thromboembolism (VTE) and atrial fibrillation (AF) are common causes of mortality and morbidity, with rising prevalence and medical costs [1] [2] [3]. Oral anticoagulation therapy (OAT) reduces thromboembolic events in AF, prosthetic heart valves, acute myocardial infarction and other conditions, and is an effective treatment for VTE [4] [5] [6]. The major risks of OAT are bleeding complications, with a rate of major bleeding among long-term users of vitamin K antagonists (VKAs) of 1.5-5.2% per year [7] [8] [9]. There is a narrow therapeutic range for VKA, expressed as the international normalized ratio (INR) with an optimal intensity, related to a low rate of events, between 2.5 and 4.9 [10] [11]. This is relevant, as patients have considerable difficulty in maintaining adequate adherence to VKA regimens, with a significant effect on anticoagulation control [12]. Structured monitoring and coaching of patients using VKA is essential. This may be carried out by specialized centers in primary care or in hospitals [13]. Alternatively, patients might choose to self-manage their VKA monitoring. In the case of VKA, self-management includes monitoring INR values by patients (self-monitoring) and, as a possible next step, self-adjustment of the medication dosage (self-dosage). Nowadays, patients are usually supported by improved eHealth supported self-management programs [14] with more freedom, improved quality of life and self-efficacy, and less burden of specialized centers [15] [16]. Research shows a reduction of thromboembolic events and in all-cause mortality for patients with self-management [17], due to the fact that patients have greater responsibility, increased awareness, commitment and interest in their condition [18].

Adequate self-management is important for all patients with OAT to improve adherence to medication, irrespective of the type of anticoagulation medicine they use [19] [20] [21]. The basic principle of self-management is behavioral change, which is necessary to improve the quality of life of patients and the primary outcomes of their health and disease [22]. Research on chronic diseases such as diabetes [23], COPD [24], and heart failure [25] has shown that aspects such as self-efficacy (belief in one's capabilities to organize and execute the course of action required to produce given attainments), educational level, socioeconomic status (SES), age and sex are influencing factors in successful self-management and predictors in eHealth usage [26].

As education is the basic approach in the development of self-management skills, the strategy used to implement educational support is expected to affect the individual level of self-management and, thereby, clinical outcomes. To test this hypothesis, we designed the PORTALS study. The aim of this study was to analyze the effect on anticoagulation control of an intervention consisting of an education program in combination with the use of an online self-management portal. The general

definition of self-management is the individual's ability to manage the symptoms, treatment, physical and psychosocial consequences and life style changes inherent in living with a chronic condition [27]; in line with this definition, both self-monitoring and self-dosage of medication are considered important self-management skills in the PORTALS study.

Methods

Study design

For the PORTALS study, we designed a quality improvement intervention and compared strategies in an implementation study [28]. Two methods were developed to train long-term VKA patients of the Saltro Thrombosis Service (outpatient anticoagulation clinic and laboratory) in self-management routine care. Using this design, we aimed to examine the influence of the training strategy on clinical outcomes and usage of the supporting eHealth platform. Full methodological details are reported elsewhere [29]; Table 1 presents an overview of the study design.

Table 1. Overview of the study design: details of groups 1, 2 and 3

Saltro Thrombosis Service Centre			
		Self-Management	Usual Care
Patients	Group 1	Group 2	Group 3
	#72	#72	#72
Instruction	E-Learning Disease-specific knowledge Self-testing skills Use of the web-portal (voluntary) Self-adjustment of medication	Group Course Disease-specific knowledge Self-testing skills Use of the web-portal (voluntary) Self-adjustment of medication	Basic Short Training
Platform	Self-management	Self-management	

A parallel cohort design was used to investigate determinants of optimal implementation of self-management by comparing two different training methods. After inclusion, participants were randomly divided into subgroups: one group was trained and educated by e-learning (group 1) and the other group received face-to-face group training (group 2). Patients unable or unwilling to dose

1
2
3 their medication were free to continue with only self-monitoring. Patients who did not wish to start
4 with self-management were invited to participate in the non-self-management group, i.e. a parallel
5 cohort group receiving usual care (group 3). Group 3 provided valuable information about the
6 patients who were unable/unwilling to use an online supported self-management program.
7
8

9
10
11 Based on our parallel cohort design, comparison between e-learning and group training for self-
12 management (group 1 and 2) and non-self-management patients (group 3) is applicable, considering
13 the specific conditions in the choice of the statistics.
14

15 16 17 18 Participants

19 The present study focused on patients of the Salthro Thrombosis Service who voluntarily chose to
20 start with self-management. The inclusion criteria for patients to start with self-management were a
21 long-term indication for anticoagulants, internet access, and stable INR values (at least three INR
22 values in succession must be within therapeutic range). Patients who met the criteria for self-
23 management were approached for participation in the study. Because self-management (including
24 eHealth) is already an option for patients of the Salthro Thrombosis Service, the group training was
25 also open to patients who were not willing to participate in the study. The e-learning was reserved
26 for participants of the present study, as this was a new implementation method. All patients
27 provided written informed consent before participation in the study.
28
29
30
31
32
33

34 35 36 Patient involvement

37 Patients were neither involved in the design, nor in defining research questions and outcome
38 measures of the study; however, they were actively involved in the development of the self-
39 management platform Portavita. To maximize the involvement of patients we did not randomize the
40 intervention groups (self-management and usual care); we chose a recruitment design in which
41 patients of the Thrombosis Service voluntarily chose to start with self-management. During the study
42 patients could give feedback on the intervention and on the self-management platform; their
43 satisfaction was continuously monitored. Feedback from patients made it possible to optimize their
44 care. All patients will be informed about the results of this study.
45
46
47
48
49
50

51 52 53 Recruitment of patients and non-participation

54 Patients of the Salthro Thrombosis Service who received regular care without a self-management
55 program were eligible for recruitment. In 2013, 8950 patients received usual care from the Salthro
56 Thrombosis Service of which 85% had a long-term indication. From June 2013 onward, a random
57
58
59
60

selection of 1632 patients was approached for participation in the present study using three methods, i) information and invitation by letter, ii) personal invitation by specialized nurses, and iii) invitation by telephone. Patients who did not wish to start with self-management were invited to participate in a parallel cohort group receiving usual care (group 3), thereby providing valuable information about non-participants. Baseline characteristics of all regular patients of the Saltro Thrombosis Service also provided valuable information about non-participants.

Intervention

The intervention in group 1 and 2 consisted of a training program in combination with the use of an online self-management portal called Portavita. In group 1, patients used an e-learning that was specifically designed for the PORTALS study (Multimedia Appendix 1).

Table 2 summarizes the programs in all groups: the e-learning modules in group 1, the group training modules in group 2, and the basic training in group 3. In group 1 the training was provided by e-learning that started with a personal login procedure and an online instruction; the interim control and quality checks were carried out by specialized nurses of the Thrombosis Service. The group course in group 2 was carried out by specialized and expert healthcare professionals. Both training methods had the same content, but were offered in a completely different manner.

Table 2. Training methods in group 1, 2 and 3.

Group 1	Group 2	Group 3
General education (e-learning) about anticoagulation + test Selftesting device Training (e-learning) selftesting + use of web portal Three months of e-learning + selftesting	Group course with training selftesting + use of web portal Three weeks practice at home Group course about anti coagulation Three months of training at home	Basic training
Selftesting device	Selftesting device	Venipuncture at home or in facilities

Control and quality check by nurse Continuing self-management program + Control and quality check by nurse every six months	Control and quality check by nurse Continuing self-management program + Control and quality check by nurse every six months	Written instructions by thrombosis doctor
---	---	---

In the PORTALS study, the online self-management portal used is called Portavita (Multimedia Appendix 2). This application combines a patient portal and a healthcare provider portal. The healthcare portal leaves space for the OAT protocol, medication records, and information about complications. The Portavita Anticoagulation Self-management patient portal has become widely accepted; it provides patients with a diary tool for self-monitoring and self-dosage, education, it also allows personal notes, and healthcare professionals can send advice and notes to the patient. It implies that the patient analyzes a drop of blood using a home INR monitor. The patient can access the web-based patient portal to enter the INR and specific information for the health professional (intervention, bleeding, change in medication, vacation, etc.). Clinically validated inbuilt algorithms provide advice regarding the next dose and test interval. The only things needed are an internet connection and a device like a PC, tablet or smartphone. When logging on (username + password) for the first time to Portavita, every user was directed to the homepage. From there, users could access all functionalities of the portal. The logon procedure of this portal is based on Dutch security legislation and guidelines (the Dutch Personal Data Protection Act).

Data collection

INR values, thromboembolic events, bleedings, medication and indication were monitored and registered continuously by patients in the portal and by professionals of the Saltro Thrombosis Service. We measured the INR, complications and medication during a period of 6 months before and 18 months after starting the intervention (i.e. 24 months in total). The data collection also consisted of questionnaires (at baseline, and after each 3 x 6-month period) to measure the determinants and outcomes. Patients of group 1 and 2 received these questionnaires by e-mail, and patients in group 3 by e-mail or by post. In addition, the number of self-tests and use of the portal were continuously registered in the portal. Data on the total population of the Saltro Thrombosis Service were also collected.

Outcome measures and determinants

The primary outcome of this study was therapeutic control expressed as the INR control over time and severe complications (bleedings and thromboembolic events). To summarize the INR control over time, the percentage of time in therapeutic range (TTR) of INR was used, calculated with the Rosendaal method [30]. TTR values were calculated for two INR ranges (INR 2-3 and INR 2-3.5) because different calculations are used in Dutch and in international guidelines. TTR was measured at four moments: at 6 months before intervention, and at 3 x 6-month periods (total of 18 months) after starting the intervention. Serious complications were defined as those needing treatment or medical evaluation. An independent thrombosis specialist was responsible for classifying serious complications at the end of the trial. The total follow-up period for all these measures was 24 months.

Furthermore, the self-management skills of participants were evaluated. Self-management skills were defined as usage of the self-management platform, reflected as the amount of login sessions. Self-monitoring and self-dosage are registered within the same login session. The usage counts were analyzed. The determinants were self-efficacy and socio-demographic characteristics. Self-efficacy was measured at baseline using the Generalized Self-Efficacy Scale (GSES), with items scored on a four-point scale with a higher score reflecting higher self-efficacy [31]. Socio-demographic characteristics were assessed by an online questionnaire addressing the following characteristics: age, gender, education level, marital status, working status (labor), and quality of life (QoL), which was assessed using the EuroQoL-5D (EQ-5D) and displayed at baseline. The EQ-5D is a 5-item questionnaire with a higher score reflecting a higher QoL.

Sample size and statistical methods

To detect a relevant effect of the new implementation strategy of e-learning or group training (>5%) [32] at a power 80% and $\alpha=0.05$, we calculated that a sample size of 63 patients was required per group. Considering a 15% drop out, 72 (63/0.85) patients were needed per study group. Baseline characteristics between the three groups were explored using Chi-square tests and Kruskal-Wallis tests.

To investigate the effect of the different implementation methods of training versus the parallel cohort group on TTR, multilevel linear regression modeling (mixed models) was used. First, TTR outcomes were compared between the three groups. A second (mixed models) analysis was used to compare the difference in effect between e-learning and group training (group 1 vs. group 2) on TTR.

The variable TTR was included as outcome in the model. The periods of TTR measurements (time), the group and the interaction term (time*group) were included as predictors.

Both analyses were adjusted for age and gender.

To examine the impact of GSES and education on the effect of the different implementation methods, multiple linear regression analyses were performed with TTR at time point 3 as outcome, and GSES and education as predictors. Analyses were adjusted for age and gender.

A linear regression analysis was used to analyze usage (mean number of login sessions) of the portal Portavita in group 1 and 2.

Results

A total of 1632 VKA patients of the Saltro Thrombosis Service were invited to participate, of which 56% (n=915) declined (Figure 1). Patients were invited in three different ways: by letter (n=475), by personal invitation during a visit to the Thrombosis Service (n=692) and by telephone (n=465). 717 patients were interested in participation in the study; 247 patients eventually signed an informed consent. During the process of inviting patients for the PORTALS study, patients were asked about their reasons for not participating: the main reasons were not having a computer or internet, no digital skills, the effort of participating in a trial, and their high level of satisfaction with usual care.

Participants were included in the study only after providing written informed consent but, because some patients failed to do this, 247 participants were finally included. Of these, 110 continued to receive regular care (group 3) and 137 patients were randomly divided into group 1 and 2 using a computer program. After randomization, 63 patients were included in group 1 (e-learning) and 74 in group 2 (group training). Figure 1 summarizes the recruitment process, including the reasons for loss to follow-up.

Characteristics of the total population of the Thrombosis Service

The characteristics of all VKA patients of the Saltro Thrombosis Service in 2015 are shown in Table 3.

Table 3. Clinical characteristics of the population of the Saltro Thrombosis Service.

Total patients N	11132
-------------------------	-------

Male N (%)	6009 (54.0)
Self-management N (%)	1986 (17.8)
Male self-management N (%)	1260 (63.4)
Medication	
Acenocoumarol N (%)	8360 (75.1)
Phenprocoumon N (%)	2761 (24.8)
Warfarin N (%)	11 (0.1)
Indications	
AF N (%)	7430 (66.8)
Ven thromboembolism N (%)	1673 (15.0)
Artificial valve N (%)	720 (6.5)
Other N (%)	1309 (11.8)
Severe complications	
Major bleedings N (%)	219 (2.0)
Thromboembolism N (%)	85 (0.8)

Baseline characteristics of study participants

Table 4 presents the baseline characteristics of the participants: median age was 66.9 years, and median TTR was 54.7 (for INR range 2-3) and 79.1 (for INR range 2-3.5). Of these patients, 66% had an indication of AF and 77.3% used acenocoumarol as oral anticoagulation medication. No significant differences were found between the three groups for gender ($\chi^2=0.38$, $p=0.826$), TTR ($\chi^2=3.68$, $p=0.159$), indication ($\chi^2=8.33$, $p=0.215$), and marital status ($\chi^2=7.47$, $p=0.280$). The three groups differed significantly on age ($\chi^2=19.96$, $p=0.0$), baseline GSES ($\chi^2=15.08$, $p=0.001$) and EQ-5D ($\chi^2=6.66$, $p=0.036$), use of medication ($\chi^2=15.23$, $p=0.004$), education level ($\chi^2=23.72$, $p=0.00$), and work status ($\chi^2=13.01$, $p=0.043$) (Table 4).

Table 4. Baseline characteristics of patients with VKA therapy in the PORTALS study

	Group 1	Group 2	Group 3	p-value	Total
N	63	74	110		247
Age in years* [IQR]	65.0 ^a [56.2-67.7]	65.8 ^a [56.4-70.4]	69.6 ^b [64.0-74.9]	0.00**	66.9 [59.5-72.7]
Males N (%)	47 (74.6)	52 (70.3)	81 (73.6)	0.826	180 (72.9)
TTR INR range 2-3 (%)* [IQR]	50.2 [39.1-67.1]	52.9 [39.0-68.6]	57.4 [40.1-75.1]	0.159	54.7 [39.8-70.7]
TTR INR range 2-3.5 (%)* [IQR]	76.3 [67.0-86.0]	77.1 [64.1-85.3]	85.6 [72.0-93.5]	0.159	79.1 [68.2-88.8]

	GSES* [IQR]	3.5 ^a [3.1-3.8]	3.3 ^{a,b} [3.0-3.7]	3.1 ^b [2.9-3.5]	0.001**	3.3 [3.0-3.7]
	EQ5D* [IQR]	1.0 ^a [0.81-1.0]	0.84 ^{a,b} [0.78-1.0]	0.84 ^b [0.78-1.0]	0.036**	0.84 [0.81-1.0]
	Indication					
	AF N (%)					
	Ven thromboembolism N (%)	42 (66.7)	44 (59.5)	77 (70.0)	0.215	163 (66)
	Artificial valve N (%)	13 (20.6)	18 (24.3)	11 (10.0)		42 (17)
	Other N (%)	2 (3.2)	3 (4.1)	4 (3.6)		9 (3.6)
		6 (9.5)	9 (12.2)	18 (16.4)		33 (13.4)
	Medication					
	Acenocoumarol N (%)	51 (81) ^a	64 (86.5) ^a	76 (69.1) ^b	0.004**	191 (77.3)
	Phenprocoumon N (%)	10 (15.9) ^a	10 (13.5) ^a	34 (30.9) ^b		54 (21.9)
	Warfarin N (%)	2 (3.2) ^a	0 (0) ^a	0 (0) ^a		2 (0.8)
	Education level					
	Low N (%)	7 (12.1) ^a	13 (19.1) ^a	33 (35.9) ^b	0.00**	53 (24.3)
	Medium N (%)	24 (41.4) ^a	32 (47.1) ^a	46 (50.0) ^a		102 (46.8)
	High N (%)	27 (46.6) ^a	23 (33.8) ^b	13 (14.1) ^c		63 (28.9)
	Marital status					
	Married N (%)	49 (84.5)	50 (73.5)	73 (79.3)	0.280	172 (78.9)
	Widow N (%)	1 (1.7)	6 (8.8)	4 (4.3)		11 (5.0)
	Divorced N (%)	1 (1.7)	6 (8.8)	4 (4.3)		11 (5.0)
	Single N (%)	7 (12.1)	6 (8.8)	11 (12.0)		24 (11.0)
	Labour					
	No paid work N (%)	28 (48.3) ^a	29 (42.6) ^a	39 (42.4) ^a	0.043**	96 (44.0)
	Paid work N (%)	19 (32.8) ^a	20 (29.4) ^a	14 (15.2) ^b		53 (24.3)
	Household N (%)	8 (13.8) ^a	11 (16.2) ^a	23 (25.0) ^a		42 (19.3)
	Incapacitated N (%)	3 (5.2) ^a	8 (11.8) ^a	16 (17.4) ^a		27 (12.4)

*Values are medians and corresponding Interquartile Ranges [IQR]

** Between-group differences (P < 0.05) are indicated by **

Each superscript (a,b,c) letter denotes a subset of sample categories which do not differ significantly from each other at the 0.05 level.

TTR is the therapeutic international normalized ratio (INR) range, GSES is the General Self-efficacy Scale, EQ5D EuroQol five dimensions questionnaire is a standardized instrument for use as a measure of health outcome.

N Missing questionnaires: GSES 29, EQ5D 32, indication 0, medication 0, education 29, marital status 29, labour 29.

Therapeutic control before and after intervention

Figure 2A shows the TTR values using the INR 2-3 in the three groups, 6 months before the intervention and in the 3 x 6-month periods after the intervention; the TTR values using the INR 2-3.5 are presented in Figure 2B (Appendix 3).

Analysis of the three groups showed no significant difference in TTR values over time ($F_{3,631}=0.755$, $p=0.520$), between the groups ($F_{2,211}=0.924$, $p=0.398$), or between the groups over time ($F_{6,631}=1.009$, $p=0.418$).

Analysis of the two self-management groups showed no significant differences in TTR values between the four time periods ($F_{3,378}=0.602$, $p=0.614$). Also, no significant differences in TTR were found between group 1 and 2 ($F_{3,378}=0.548$, $p=0.460$) or between these two groups over time ($F_{3,378}=1.335$, $p=0.263$).

The sensitivity analyses showed that using an INR of 2-3.5, instead of 2-3, had no marked effect on the results, although a significant time effect was found. Results are presented in figure 2B in Appendix 3.

During the 18-month period after the intervention, across all three groups, a total of 3 severe complications occurred (3/247=1.2%): i.e. two muscular bleedings in the e-learning group (2/63=3.2%) and one cerebrovascular accident among patients receiving group training (1/74=1.4%); no complications occurred in the usual care group.

Educational level and GSES

Educational level was not associated with the TTR in the last 6 months ($F_{2,198}=2.263$, $p=0.107$); education level did not modify the effect of the different implementation methods on TTR ($F_{4,198}=1.659$, $p=0.161$).

No association was found between the GSES and TTR in the last 6 months ($F_{1,198}=0.132$, $p=0.717$); GSES did not modify the effect of the different implementations methods on TTR ($F_{2,198}=1.762$, $p=0.174$).

Usage of the platform

Figure 3 presents the usage by patients in group 1 and 2 (using the logfiles of the Portavita platform) during the 18 months after start of the intervention. Patients logged on to the platform to register

1
2
3 their INR; some also used it to establish their medication dosage or to communicate with healthcare
4 professionals of the Thrombosis Service. There was no significant difference between group 1 and 2
5 in usage of the platform during the three time periods (0-6 months: mean 20.75 , SD 5.20 , $F_{1,109}$
6 =0.091, $p=0.764$; 6-12 months: mean 13.00, SD 7.0, $F_{1,109}=0.029$, $p=0.866$; 12-18 months: mean 12.5,
7 SD 7.39, $F_{1,109}=1.28$, $p=0.260$).

11 Discussion

12
13
14 In the present study, no differences were found in therapeutic control and usage of the platform
15 between anticoagulation self-management patients trained by e-learning and by group training.
16 Moreover, the clinical results for self-management patients were similar to those of patients
17 receiving regular care. Therefore, we conclude that, with adequate training through e-learning or
18 group training, self-management is safe and reliable for a selected proportion of motivated patients
19 receiving VKA. The PORTALS study provides valuable information on different implementation
20 methods of OAT self-management, including eHealth.
21
22
23
24
25
26
27
28

29 Strengths and limitations

30
31 This PORTALS study has several strengths. First, the study investigates the effect of different
32 education programs in a situation as close to 'real life' as possible, integrated in a self-management
33 program including eHealth, on clinical outcomes and self-management skills. The study also adds
34 evidence to the existing body of knowledge on implementation of eHealth; this is important because
35 local political/financial factors have a major impact on successful integration of eHealth in daily
36 practice and because self-management is important for patients who will use VKAs in the future [33].
37
38
39
40
41

42 This study also has limitations. First, a randomized controlled trial (RCT) was not feasible in our
43 setting of an implementation design in a real-life healthcare system with patients who have differing
44 demands. Instead, an observational study was considered the best option for our context, i.e.
45 patients cannot be denied or forced to start with self-management. Furthermore, self-management
46 skills imply behavioral changes. However, behavioral changes require time, whereas the study period
47 was restricted to 18 months. This study also has limitations typically associated with eHealth trials.
48 For example, as patients were free to volunteer, bias might have occurred in our study groups. Users
49 were self-selected and were, presumably, motivated to use the education program (including the
50 web-based platform) as would be expected in a real-life setting. Of the 1632 invited OAT patients,
51 247 patients (15%) were willing to participate and provided informed consent. However, only 137
52
53
54
55
56
57
58
59
60

1
2
3 patients (8.4% of invited patients) wanted to participate in the self-management groups and were
4 randomized; other studies have a similar low recruitment rate for self-management trials [34]. This
5 phenomenon might have affected the measurability of differences and might also reduce differences
6 between the groups. The high number of participants lost to follow-up in our study (“law of
7 attrition”; the phenomenon of participants stopping usage) is a common finding in eHealth
8 evaluations and one of the fundamental and methodological challenges in the evaluation of eHealth
9 apps [35]. The loss to follow-up is high with a risk of biased results due to user bias; therefore, these
10 results are only applicable for users of eHealth.

11
12 The total population of the Thrombosis Service showed a lower percentage of men than the
13 participants of the present study, although the distribution of indications/medication was similar. In
14 the total population, the percentage of severe complications was low (bleedings 2%,
15 thromboembolism 0.8%); during our study period the percentage of complications was also low
16 (group e-learning =3.2%; group training =1.4%; group usual care =0%), indicating a high quality of
17 thrombosis care.

18
19 During the process of inviting patients for the PORTALS study, we asked their reasons for not
20 participating (main reasons were: not having a computer/internet, no digital skills, the effort of
21 participating, and their high level of satisfaction with usual care). The group with usual care differed
22 significantly from the self-management groups on several baseline characteristics: i.e. patients in
23 usual care were older, had a lower education level, and fewer of them had paid work. Also, they had
24 a lower GSES and EQ5D, and made less use of acenocoumarol. Patients in the total population of the
25 Thrombosis Service, and in the usual care group, might have different wishes and expectations
26 towards care than patients that chose for a self-management program; i.e. self-management
27 programs are suitable for patients that are highly motivated and have skills for self-management
28 tasks.

29
30 Finally, to measure a significant difference in therapeutic control, 72 patients were needed in each
31 group. Although these numbers were not entirely met in group 1 (e-learning), analysis of the groups
32 should be sufficiently powered to detect relevant differences. In addition, the high number of INR
33 data points collected before and after the intervention has a substantial impact on the strength of
34 the design and the multilevel linear analysis.

35
36 Due to these limitations, caution is required when generalizing our results to general practice.
37 However, the practical applicability of our results for other specialized OAT centers is positive, i.e. the

1
2
3 study provides practical insight into successful implementation of self-management programs
4 consisting of high-quality training and usage of a patient platform.
5
6
7

8 Interpretation of findings 9

10 No overall significant differences in therapeutic control were found between the three groups; also,
11 there was no difference in therapeutic control between the group with e-learning and group training.
12 Therapeutic INR control was good in all groups; in the last 6 months of the intervention period, all
13 groups spent around 58% of time within the narrow therapeutic range 2-3 and 83% of time within
14 the therapeutic range 2-3.5; this indicates high quality and is comparable to other studies [34] [36].
15 Anticoagulation control levels around 60% for TTR of INR range 2-3 are considered safe [36] [37] [38].
16 In studies conducted outside specialized care facilities in several different regions, TTR ranged from
17 40-70% [13]. The national guidelines for the INR range changed during the last 6 months of our
18 PORTALS study; this had a negative impact on the TTR during our last measurement period.
19 Complication rates also compared favorably with international data; our overall adverse event rate
20 was low compared to other studies [39] [40] [41].
21
22

23 In comparison to literature, the baseline quality of OAT management in the present study can be
24 considered high in all groups; therefore, further improvement through a self-management program
25 including education was difficult to achieve and the outcomes in the groups remained the same.
26 Finally, both training methods were comparable on the effect of anticoagulation control; for patients
27 and healthcare professionals this means that a good e-learning program is a good alternative for
28 labour intensive group trainings. Based on our study, we recommend considering self-management
29 programs supported by e-learning as the preferred plan of action for self-management for
30 anticoagulation patients. Furthermore, self-management with an e-learning component is suitable
31 for motivated patients with sufficient digital skills; in our opinion, regular anticoagulation care needs
32 to remain available for the rest of the population.
33
34
35
36
37
38
39
40
41
42
43
44

45 Self-efficacy and educational level of users had no impact on therapeutic control for the different
46 implementation methods. The construct of perceived self-efficacy reflects an optimistic self-belief
47 [31]; a correlation can be understood based on the belief that one can perform a novel or difficult
48 task, or cope with adversity (indicating a higher self-efficacy). In the present study, self-efficacy was
49 comparable to that in a healthy Dutch population [42] [43].
50
51
52
53
54

55 The practical value of the Portavita portal is very high for patients, because of the functionalities of
56 self-monitoring, self-dosage and digital advice from professional healthcare providers. Because
57
58
59
60

1
2
3 patients use the self-management program, regular visits to medical facilities are unnecessary.
4 Patients can manage their anticoagulation in their own time and in their own chosen place. Thus,
5 using the self-management program gives them (extra) freedom; this might be a strong motivating
6 factor for using the program. Also, the training programs were sound and sustainable during the
7 entire study period, probably stimulating patients to persevere with their self-management program.
8 Moreover, e-learning and group training led to the same usage and, therefore, the same self-
9 management skills. Therefore, we conclude that our e-learning and group training provide a good
10 start for OAT patients that voluntarily start with a self-management program including eHealth.
11
12

13
14
15
16
17 Self-management programs with eHealth technologies for chronic conditions can be used to enhance
18 self-management and revise the Chronic Care Model; patients who actively participate in their care
19 achieve valuable and sustained improvement in wellbeing [44] [45]. In many eHealth studies, use of a
20 Personal Health Record or self-management platform can promote an informed/activated patient
21 and augment the Chronic Care Model for self-management support and productive interactions;
22 even though a direct dosage-effect relation (usually analyzed in a classical RCT) is not common in
23 eHealth [46]. Self-management programs with good training and practical eHealth platforms have
24 the potential to make chronic care personalized in a blended care model; every patient needs a
25 different approach for optimal therapeutic control. Healthcare providers need to embrace a different
26 role and release tight protocols [47]. Individual patients have different expectations and wishes,
27 which should be a topic of conversation with each patient. The general scientific basis for self-
28 management applies perfectly to anticoagulation patients, which is confirmed in our study.
29
30
31
32
33
34
35
36
37

38 More studies are needed (preferably with larger sample groups, and including non-users) to gain
39 more insight into the preferences of various patient groups, as well as the related costs.
40 The substantial workload generated by integrating a web-based platform in an OAT self-management
41 program emphasizes the importance of piloting and assessing workforce implications for OAT
42 management centers. The present results provide additional insight into the organizational aspects
43 of the implementation of education programs into a self-management program with a platform,
44 including the need to educate and coach patients in the use of web-based platforms.
45
46
47
48
49
50

51 Conclusion

52
53 Our main finding is that there were no differences in therapeutic control and usage of a supporting
54 eHealth platform between anticoagulation self-management patients trained by e-learning and by
55 group training. Moreover, we found that clinical results for self-management patients are
56
57
58
59
60

1
2
3 comparable to those of patients receiving usual care. We conclude that with appropriate and sound
4 training through e-learning or group training, self-management is safe and reliable for a selected
5 proportion of motivated patients receiving oral anticoagulation treatment. The PORTALS study
6 provides valuable information on different implementation methods of oral anticoagulation self-
7 management, including eHealth.
8
9
10

11 Acknowledgments

12 The authors wish to thank all patients and caregivers within the Saltro Thrombosis Service Centre.
13 The authors thank Pim Assendelft for his valuable contribution to the design and Joke van der Feest,
14 Nynke Wiersma, Carola Guse and Sandra Claassen for their research assistance. The authors also
15 thank Nan van Geloven for reviewing the statistical analysis.
16
17
18
19
20
21
22

23 Data sharing

24 Data will be made available for sharing where available and appropriate.
25
26
27
28

29 Transparency declaration

30 The lead author affirms that the manuscript is an honest, accurate, and transparent account of the
31 study being reported; that no important aspects of the study have been omitted; and that any
32 discrepancies from the study as planned (and, if relevant, registered) have been explained.
33 All authors, external and internal, had full access to all of the data (including statistical reports and
34 tables) in the study and can take responsibility for the integrity of the data and the accuracy of the
35 data analysis.
36
37
38
39
40
41
42

43 Ethics and consent to participate

44 This study is conducted according to the principles of the Declaration of Helsinki (version 59, 2008)
45 and in accordance with the Medical Research Involving Human Subjects Act (WMO). Participants
46 were only included in the study after written informed consent was received. The Medical Ethics
47 Committee of the LUMC approved this study (Reference No. P12.278).
48
49
50
51
52

53 Competing interests

54 All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf
55 and declare: no support from any organization for the submitted work; no financial relationships
56
57
58
59
60

with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Funding

This work was supported by the Foundation Care Within Reach (in Dutch: Stichting Zorg Binnen Bereik).

Author's contributions

ET is the principle investigator and contributed to all aspects of the research. NV assisted on all aspects. MK assisted on the statistical analysis and is responsible for revising the manuscript several times. LH is responsible for revising the manuscript several times. IT is responsible for the acquisition of data and revising the manuscript several times. MN is responsible for revising the manuscript. NC is responsible for the concept, design, and for revising the manuscript. All authors read and approved the final manuscript.

References

1. Streiff MB, Carolan HT, Hobson DB, Kraus PS, Holzmueller CG, Demski R, Lau BD, Biscup-Horn P, Pronovost PJ, Haut ER. Lessons from the Johns Hopkins Multi-Disciplinary Venous Thromboembolism (VTE) Prevention Collaborative. *BMJ*. 2012 Jun 19;344:e3935. DOI: 10.1136/bmj.e3935.
2. CBO Richtlijn Diagnostiek, preventie en behandeling van Veneuze trombo-embolie en Secundaire Preventie Arteriele trombose 2009 [*CBO Diagnostics Guidelines, prevention and treatment of venous thromboembolism and secondary prevention of arterial thrombosis 2009*].
3. Schnabel RB et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet* , Volume 386 , Issue 9989 , 154 – 162. July 2015. DOI: [http://dx.doi.org/10.1016/S0140-6736\(14\)61774-8](http://dx.doi.org/10.1016/S0140-6736(14)61774-8).
4. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek ME, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GYH. Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2_suppl):e531S-e575S. doi:10.1378/chest.11-2304.
5. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP. Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After

- 1
2
3 Isolated Calf Deep Vein Thrombosis. *Circulation* May 22, 2001, Volume 103, Issue 20.
4 doi: <https://doi.org/10.1161/01.CIR.103.20.2453>.
5
6 6. Torn M, Bollen WLE, Meer van der FJM, Wall van der EE, Rosendaal FR. Risks of Oral Anticoagulant
7 Therapy With Increasing Age. *Arch Intern Med*. 2005;165:1527-1532.
8 doi:10.1001/archinte.165.13.1527.
9
10 7. Heneghan C, Ward A, Perera R, Self-Monitoring Trialist Collaboration, Bankhead C, Fuller A, et al.
11 Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient
12 data. *Lancet* 2012 Jan 28;379(9813):322-334 doi: 10.1016/S0140-6736(11)61294-4.
13
14 8. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of Intensity of Oral
15 Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. *N Engl J Med* 2003;349:1019-
16 26. DOI: 10.1056/NEJMoa022913.
17
18 9. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in
19 patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis.
20 *Blood* 2014 124:2450-2458; doi: <https://doi.org/10.1182/blood-2014-07-590323>
21
22 10. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E.
23 Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart Valves. *N Engl J Med* 1995;
24 333:11-17. July 6, 1995. DOI: 10.1056/NEJM199507063330103.
25
26 11. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI,
27 Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, Nguyen P, Demers C, Kahn SR, Kassis J,
28 Rodger M, Hambleton J, Gent M. Comparison of Low-Intensity Warfarin Therapy
29 with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous
30 Thromboembolism. *N Engl J Med* 349;7. DOI: 10.1056/NEJMoa035422.
31
32 12. Kimmel SE, Chen Z, Price M, Gross R. The Influence of Patient Adherence on Anticoagulation
33 Control With Warfarin; Results From the International Normalized Ratio Adherence and Genetics (IN-
34 RANGE) Study. *Arch Intern Med*. 2007;167(3):229-235. DOI: 10.1001/archinte.167.3.229.
35
36 13. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC,
37 Breithard G, Hankey JG, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KAA. Impact of Global
38 Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the
39 ROCKET AF Clinical Trial. *J Am Heart Assoc*. 2013;2:e000067 doi: 10.1161/JAHA.112.000067.
40
41 14. McLean S, Protti D, Sheikh A. Telehealthcare for long-term conditions. *BMJ* 2011;342:d120. doi:
42 10.1136/bmj.d120.
43
44 15. Gadisseur APA, Kaptein AA, Breukink-Engbers WGM, van der Meer FJM, Rosendaal FR. Patient
45 self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics:
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 positive effects on quality of life. *J Thromb Haemost* 2004 Apr;2(4):584-591. DOI: 10.1111/j.1538-
4 7836.2004.00659.x.
5
6 16. McCahon D, Murray ET, Murray K, Holder RL, Fitzmaurice DA. Does self-management of oral
7 anticoagulation therapy improve quality of life and anxiety? *Fam Pract* 2011 Apr;28(2):134-140.
8 DOI: 10.1093/fampra/cm089.
9
10 17. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, Alonso-Coello P,
11 Fitzmaurice D, Mahtani KR, Onakpoya IJ. Self-monitoring and self-management of oral
12 anticoagulation. *Cochrane Heart Group* 2016. DOI: 10.1002/14651858.CD003839.pub3.
13
14 18. Newman S, Steed L, Mulligan K. Self-management interventions for chronic illness. *Lancet* 2004;
15 364: 1523–37. DOI: 10.1016/S0140-6736(04)17277-2.
16
17 19. Bouillon K, Bertrand M, Maura G, Blotière PO, Ricordeau P, Zureik M. Risk of bleeding and arterial
18 thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K
19 antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-
20 cohort study. *Lancet Haematol* 2015 Apr;2(4):e150-9. doi: 10.1016/S2352-3026(15)00027-7.
21
22 20. Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, et al. Safety and effectiveness of
23 oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein
24 thrombosis (XALIA): An international, prospective, non-interventional study. *Lancet Haematol*
25 2016;3:e12-21 . doi: 10.1016/S2352-3026(15)00257-4.
26
27 21. Lin L, Lim WS, Zhou HJ, Khoo AL, Tan KT, Chew AP, et al. Clinical and safety outcomes of oral anti-
28 thrombotics for stroke prevention in atrial fibrillation: A systematic review and network meta-
29 analysis. *J Am Med Dir Assoc* 2015;16:1103.e1-19. doi: 10.1016/j.jamda.2015.09.008.
30
31 22. Lorig K, Ritter P, Stewart A, Sobel D, Brown B, Bandura A, Gonzalez V, Laurent D, Holman H.
32 Chronic Disease Self-Management Program. 2-Year Health Status and Health Care Utilization
33 Outcomes. *Med Care*. 2001 Nov;39(11):1217-23. PMID: 11606875.
34
35 23. Mishali M, Omer H, Heymann A. The importance of measuring self-efficacy in patients with
36 diabetes. *Fam Pract*. 2011 Feb;28(1):82-7. doi: 10.1093/fampra/cm086.
37
38 24. Simpson E, Jones MC. An exploration of self-efficacy and self-management in COPD patients. *Br J*
39 *Nurs*. 2013 Oct 24-Nov 13;22(19):1105-9. DOI: 10.12968/bjon.2013.22.19.1105
40
41 25. Rajati F, Sadeghi M, Feizi A, Sharifirad G, Hasandokht T, Mostafavi F. Self-efficacy strategies to
42 improve exercise in patients with heart failure: A systematic review. *ARYA Atheroscler*. 2014
43 Nov;10(6):319-33. PMID: 25815022.
44
45 26. Kontos E, Blake KD, Chou WYS, Prestin A. Predictors of eHealth Usage: Insights on The Digital
46 Divide From the Health Information National Trends Survey 2012. *J Med Internet Res*
47 2014;16(7):e172. doi:10.2196/jmir.3117.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 27. Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches for people
4 with chronic conditions: a review. *Patient Educ Couns* 2002; 48: 177–87. PMID: 12401421
- 5
6 28. van Bokhoven MA, Kok G, van der Weijden T. Designing a quality improvement intervention: a
7 systematic approach. *Qual Saf Health Care*. 2003;12:215–20. PMID: 12792013
- 8
9 29. Talboom EPWA, Verdijk NA, Talboom IJSH, Harmans LM, Numans ME, Chavannes NH. PORTALS:
10 design of an innovative approach to anticoagulation management through eHealth. *BMC Health*
11 *Services Research* (2017) 17:213 DOI 10.1186/s12913-017-2142-2
- 12
13 30. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal
14 intensity of oral anticoagulant therapy. *Thromb Haemost*. 1993;69(3):236–9. PMID: 8470047
- 15
16 31. Scholz U, Gutiérrez-Doña B, Sud S, Schwarzer R. Is general self-efficacy a universal construct?
17 Psychometric findings from 25 countries. *Eur J Psychol Assess*. 2002;18:242–51.
- 18
19 32. Heneghan C, Ward A, Perera R et al. Self-monitoring of oral anticoagulation: systematic review
20 and meta-analysis of individual patient data. *Lancet*. 2012 Jan 28;379(9813):322-34. DOI:
21 10.1016/S0140-6736(11)61294-4
- 22
23 33. Nijland N. Thesis: Grounding eHealth. Towards an holistic framework for sustainable eHealth
24 technologies. University of Twente; 2011. ISBN: 9789036531337
- 25
26 34. Gadisseur AP, Breukink-Engbers WG, Meer van der FJ, Besselaar van den AM, Sturk A, Rosendaal
27 FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and
28 management by specialized anticoagulation clinics in the Netherlands: a randomised clinical trial.
29 *Arch Int Med* 2003;163:2639-46. DOI: 10.1001/archinte.163.21.2639
- 30
31 35. Eysenbach G. The Law of Attrition. *J Med Internet Res* 2005;7(1):e11. PMID: 15829473
- 32
33 36. Menéndez-Jándula B, Souto JC, Oliver A, Montserat I, Quintana M, Gich I, et al. Comparing self-
34 management of oral anticoagulant therapy with clinic management: a randomized trial. *Ann Intern*
35 *Med* 2005;142:1-10. PMID: 15630104.
- 36
37 37. Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S, et al. Self-management
38 of oral anticoagulation: randomised trial. *BMJ* 2005 Nov 5;331(7524):1057 doi:
39 10.1136/bmj.38618.580903.AE.
- 40
41 38. Ryan F, Byrne S, O'Shea S. Randomized controlled trial of supervised patient self-testing of
42 warfarin therapy using an internet-based expert system. *J Thromb Haemost* 2009 Aug;7(8):1284-
43 1290. doi: 10.1111/j.1538-7836.2009.03497.x.
- 44
45 39. Rein van N, Lijfering WM, Bos MHA, Herruer MH, Vermaas HW, Meer van der FJM, Reitsma PH.
46 Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for
47 Major Bleeding during Treatment with Vitamin K Antagonists. *PLoS ONE* 11(12): e0164485.
48 doi:10.1371/journal.pone.0164485.
- 49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 40. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage:
4 results from the National Registry of Atrial Fibrillation (NRAF). *Am Heart J* 2006;151(3):713-719. DOI:
5 10.1016/j.ahj.2005.04.017.
6
7 41. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in
8 patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. *Blood*.
9 2014;124(15):2450-2458. DOI 10.1182/blood-2014-07- 590323.
10
11 42. Schwarzer R. Self-efficacy: Thought Control of Action. Hemisphere Publishing Corporation; 1992.
12 ISBN: 9781560322696.
13
14 43. Luszczynska A, Gutiérrez-Doña B, Schwarzer R. General self-efficacy in various domains of human
15 functioning: Evidence from five countries. *Int J Psychol* 2005; 40 (2), 80–89.
16 doi: 10.1080/00207590444000041.
17
18 44. Siminerio LM. The role of technology and the chronic care model. *J Diabetes Sci Technol* 2010
19 Mar;4(2):470-475. DOI: 10.1177/193229681000400229.
20
21 45. Stelfox M, Chaney B, Barry AE, Chavarria E, Tennant B, Walsh-Childers K, et al. Web 2.0 chronic
22 disease self-management for older adults: a systematic review. *J Med Internet Res* 2013;15(2):e35.
23 doi: 10.2196/jmir.2439.
24
25 46. Archer N, Fevrier-Thomas U, Lokker C, McKibbin KA, Straus SE. Personal health records: a
26 scoping review. *J Am Med Inform Assoc* 2011;18(4):515-522. doi: 10.1136/amiajnl-2011-000105.
27
28 47. Sun X, Guyatt GH. Interventions to enhance self-management support. *BMJ* 2013;346:f3949. doi:
29 <https://doi.org/10.1136/bmj.f3949>.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flowchart of the PORTALS study

BMJ Open: first published as 10.1136/bmjopen-2017-017909 on 27 September 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2A. Health status based on time in therapeutic (TTR) (for INR range 2-3) for the three groups.





Figure 3. Usage of the platform in group 1 and group 2 after start of the intervention.

BMJ Open: first published as 10.1136/bmjopen-2017-017909 on 27 September 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.



Appendix 1: E-learning anticoagulation

review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Homepage from Selfmanagement, S.

Personal data
 Patient number: SELF01992765
 Most recent dosing schedule (provisional)
 Dosing period: 28-03-2017 until 17-04-2017
 Anticoagulation medication: Acenocoumarol 1 mg
 Dosing schedule created on: 28-03-2017 by Selfmanagement, S.
 Dose according to step: 25


Important data
 Dosing schedule based on INR: 3,6 measured on Tue, 28-03-2017 at 06:46
 Next Thrombosis Service check-up: **Tue. 17-01-2017 at 09:00**
 Next blood sampling date: Tue. 18-04-2017

	wk. 13	wk. 14	wk. 15	wk. 16
Mon.		3 Apr. 2	10 Apr. 2	17 Apr. 2
Tue.	28 Mar. 1	4 Apr. 2	11 Apr. 1	18 Apr. 2
Wed.	29 Mar. 2	5 Apr. 2	12 Apr. 2	19 Apr. 2
Thu.	30 Mar. 2	6 Apr. 1	13 Apr. 2	20 Apr. 1
Fri.	31 Mar. 2	7 Apr. 2	14 Apr. 2	
Sat.	1 Apr. 1	8 Apr. 2	15 Apr. 1	
Sun.	2 Apr. 2	9 Apr. 2	16 Apr. 2	

Print dosing schedule **Print holiday letter** You will need Adobe Reader to view the holiday letters. You can download this program for free [here](#).

Subject (read message)	New messages from	Date	Time
Er is een opmerking bij uw doseschema toegevoegd of gewijzigd	Trombosedienst Demo	19-01-2017	12:48
test	Trombosedienst Demo	12-01-2017	16:18

Appendix 2: Patients' self-management web portal homepage



Appendix 3: Health status based on time in therapeutic (TTR) (for INR range 2-3.5) for the three groups. Figure 2B shows TTR values using the INR 2-3.5 in the three groups, 6 months before the intervention and in the 3 x 6-month periods after the intervention. Analysis of the three groups showed that the TTR values differed significantly over time ($p=0.017$). No significant differences were found in TTR between the groups ($p=0.163$) or between the groups over time ($p=0.545$).

Analysis of the two self-management groups showed significant differences in the TTR values between the four time periods (i.e. pre- and postintervention) ($p=0.008$). There were no significant differences in TTR between group 1 and 2 ($p=0.721$) or between the groups over time ($p=0.825$).

Equivalent health status for e-learning, group training self-management or usual care in oral anticoagulation patients: a parallel cohort design in the PORTALS Study

STROBE statement, checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract		
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract – Page 1 (b) Provide in the abstract an informative and balanced summary of what was done and what was found – Page 2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported – Page 3 (Introduction)
Objectives	3	State specific objectives, including any prespecified hypotheses – Page 4 (Introduction)
Methods		
Study design	4	Present key elements of study design early in the paper – Page 5/6 (Study design) + figure 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection – Page 5 (Study design) + reference 28
Participants	6	(a) Cohort study? Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up – Page 6 (Participants) + reference 28
		(b) Cohort study? For matched studies, give matching criteria and number of exposed and unexposed Participants were not matched + figure 1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give

	Item No	Recommendation
		diagnostic criteria, if applicable – Page 8/9 (Outcome measures and determinants)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). – Page 8/9 (Outcome measures and determinants) Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias – Page 9 (Sample size and statistical methods)
Study size	10	Explain how the study size was arrived at – Page 9 (Sample size and statistical methods)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why – Page 8/9 (Outcome measures and determinants)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding – Page 9 (Sample size and statistical methods)
		(b) Describe any methods used to examine subgroups and interactions – Page 9 (Sample size and statistical methods)
		(c) Explain how missing data were addressed – Page 9 (Sample size and statistical methods)
		(d) Cohort study? If applicable, explain how loss to follow-up was addressed – Page 9 (Sample size and statistical methods)
		(e) Describe any sensitivity analyses Not applicable.
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study? eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed – Page 9/10 (Results)
		(b) Give reasons for non-participation at each stage – Page 10/11 (Baseline characteristics of study participants)
		(c) Consider use of a flow diagram Figure 2.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders – Page 10/11 (Baseline characteristics of study participants)

	Item No	Recommendation
		(b) Indicate number of participants with missing data for each variable of interest – Page 10/11 (Baseline characteristics of study participants) + Table 3
		(c) Cohort study? Summarise follow-up time (eg average and total amount) – Page 8/9 (Outcome measures and determinants)
Outcome data	15*	Cohort study? Report numbers of outcome events or summary measures over time – Page 12/13 (Usage of the platform)
Main results	16	(a) Report the numbers of individuals at each stage of the study? eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed – Page 9/10 (Results)
		(b) Give reasons for non-participation at each stage – Page 9/10 (Results)
		(c) Consider use of a flow diagram Figure 2.
Other analyses	17	Report other analyses done? eg analyses of subgroups and interactions, and sensitivity analyses Page 12 (Health status before and after intervention/Educational level and GSES)
Discussion		
Key results	18	Summarise key results with reference to study objectives – Page 13 (Discussion)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias – Page 13/14 (Strengths and limitations)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence – Page 14/15 (Interpretation of findings)
Generalisability	21	Discuss the generalisability (external validity) of the study results – Page 16 (Interpretation of findings)
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based – Page 17 (Funding)

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross sectional studies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The STROBE checklist is best used in conjunction with the explanation and elaboration article.¹⁸⁻²⁰ This article and separate versions of the checklist for cohort, case-control, and cross sectional studies are available at www.strobe-statement.org.

For peer review only

BMJ Open

Effect of a combined education and eHealth program on the control of oral anticoagulation patients (PORTALS study): a parallel cohort design in Dutch primary care

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017909.R2
Article Type:	Research
Date Submitted by the Author:	24-Aug-2017
Complete List of Authors:	Talboom-Kamp, Esther; Leiden University Medical Centre, Public Health and Primary Care Department; Saltro Diagnostic Centre Verdijk, Noortje; Leiden University Medical Centre, Public Health and Primary Care Department; Saltro Diagnostic Centre Kasteleyn, Marise; Leiden University Medical Centre, Public Health and Primary Care Department Harmans, Lara; Saltro Diagnostic Centre Talboom, Irvin; Zorgdraad Foundation Numans, Mattijs; Leiden University Medical Centre, Public Health and Primary Care Department Chavannes, Niels; Leiden University Medical Centre, Public Health and Primary Care Department
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Health informatics, Medical education and training, General practice / Family practice
Keywords:	self-efficacy, eHealth, TTR, self-management, thrombosis, oral anticoagulation

SCHOLARONE™
Manuscripts

Effect of a combined education and eHealth program on the control of oral anticoagulation patients (PORTALS study): a parallel cohort design in Dutch primary care

Esther PWA Talboom-Kamp MD MBA^{1,2}, Noortje A Verdijk MSc PhD^{1,2}, Marise J Kasteleyn MSc PhD¹,
Lara M Harmans MSc², Irvin JSH Talboom³, Mattijs E Numans MD PhD¹, Niels H Chavannes MD PhD¹

¹ Leiden University Medical Centre, Public Health and Primary Care Department
P.O. Box 9600, 2300 RC Leiden, the Netherlands

² Saltro Diagnostic Centre
Mississippidreef 83, 3565 CE Utrecht, the Netherlands

³ Zorgdraad Foundation
Wijnand van Arnhemweg 54, 6862XN Oosterbeek, the Netherlands

Corresponding author

EPWA (Esther) Talboom-Kamp MD MBA
Saltro Diagnostic Centre
Mississippidreef 83
3565 CE Utrecht
The Netherlands
Telephone: +31-30-2361170
Fax: +31-30-2361172
E-mail: e.talboom@saltro.nl

1
2
3 Abstract

4 **Objectives** To analyze the effect on therapeutic control and self-management skills of the
5 implementation of self-management programs, including eHealth by e-learning versus group
6 training.
7
8

9
10
11 **Setting** Primary Care Thrombosis Service Center.
12

13
14 **Participants** Of the 247 OAT patients, 63 started self-management by e-learning, 74 self-
15 management by group training, and 110 received usual care.
16

17
18 **Intervention and methods** Parallel cohort design with two randomized self-management groups (e-
19 learning and group training) and a group receiving usual care. The effect of implementation of self-
20 management on time in therapeutic range (TTR) was analyzed with multilevel linear regression
21 modeling. Usage of a supporting eHealth platform and the impact on self-efficacy (Generalized Self-
22 Efficacy Scale; GSES) and education level were analyzed with linear regression analysis. After
23 intervention, TTR was measured in 3 time periods of 6 months.
24
25
26
27

28
29 **Main outcome measures** i) TTR, severe complications ii) usage of an eHealth platform iii) GSES,
30 education level.
31
32

33
34 **Results** Analysis showed no significant differences in TTR between the three time periods ($p=0.520$),
35 the three groups ($p=0.460$) or the groups over time ($p=0.263$). Comparison of e-learning and group
36 training showed no significant differences in TTR between the time periods ($p=0.614$), the groups
37 ($p=0.460$) or the groups over time ($p=0.263$). No association was found between GSES and TTR
38 ($p=0.717$), or education level and TTR ($p=0.107$). No significant difference was found between the
39 self-management groups in usage of the platform (0-6 months $p=0.571$; 6-12 months $p=0.866$; 12-18
40 months $p=0.260$). The percentage of complications was low in all groups (3.2%; 1.4%; 0%).
41
42
43
44
45
46
47

48 **Conclusions** No differences were found between OAT patients trained by e-learning or by a group
49 course regarding therapeutic control (TTR) and usage of a supporting eHealth platform. The TTR was
50 similar in self-management and regular care patients. With adequate e-learning or group training,
51 self-management seems safe and reliable for a selected proportion of motivated VKA patients.
52
53
54

55
56
57 Trial Registration – NTR3947
58
59
60

1
2
3
4
5 **Keywords** – oral anticoagulation; TTR; eHealth; self-management; self-efficacy; e-learning;
6 thrombosis; self-monitoring.
7
8
9

10 Article summary

11 Strengths and limitations of this study

- 12 • This study investigates the effect of different education and eHealth programs in a situation
13 as close to 'real life' as possible;
- 14 • The pragmatic study design will increase the applicability of the findings;
- 15 • The combination of clinical and usage data collection will give a deeper comprehension of
16 the results;
- 17 • A potential limitation is that patients were free to volunteer, which might have caused bias in
18 our study groups.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Venous thromboembolism (VTE) and atrial fibrillation (AF) are common causes of mortality and morbidity, with rising prevalence and medical costs [1] [2] [3]. Oral anticoagulation therapy (OAT) reduces thromboembolic events in AF, prosthetic heart valves, acute myocardial infarction and other conditions, and is an effective treatment for VTE [4] [5] [6]. The major risks of OAT are bleeding complications, with a rate of major bleeding among long-term users of vitamin K antagonists (VKAs) of 1.5-5.2% per year [7] [8] [9]. There is a narrow therapeutic range for VKA, expressed as the international normalized ratio (INR) with an optimal intensity, related to a low rate of events, between 2.5 and 4.9 [10] [11]. This is relevant, as patients have considerable difficulty in maintaining adequate adherence to VKA regimens, with a significant effect on anticoagulation control [12]. Structured monitoring and coaching of patients using VKA is essential. This may be carried out by specialized centers in primary care or in hospitals [13]. Alternatively, patients might choose to self-manage their VKA monitoring. In the case of VKA, self-management includes monitoring INR values by patients (self-monitoring) and, as a possible next step, self-adjustment of the medication dosage (self-dosage). Nowadays, patients are usually supported by improved eHealth supported self-management programs [14] with more freedom, improved quality of life and self-efficacy, and less burden of specialized centers [15] [16]. Research shows a reduction of thromboembolic events and in all-cause mortality for patients with self-management [17], due to the fact that patients have greater responsibility, increased awareness, commitment and interest in their condition [18].

Adequate self-management is important for all patients with OAT to improve adherence to medication, irrespective of the type of anticoagulation medicine they use [19] [20] [21]. The basic principle of self-management is behavioral change, which is necessary to improve the quality of life of patients and the primary outcomes of their health and disease [22]. Research on chronic diseases such as diabetes [23], COPD [24], and heart failure [25] has shown that aspects such as self-efficacy (belief in one's capabilities to organize and execute the course of action required to produce given attainments), educational level, socioeconomic status (SES), age and sex are influencing factors in successful self-management and predictors in eHealth usage [26].

As education is the basic approach in the development of self-management skills, the strategy used to implement educational support is expected to affect the individual level of self-management and, thereby, clinical outcomes. To test this hypothesis, we designed the PORTALS study. The aim of this study was to analyze the effect on anticoagulation control of an intervention consisting of an education program in combination with the use of an online self-management portal. The general

definition of self-management is the individual's ability to manage the symptoms, treatment, physical and psychosocial consequences and life style changes inherent in living with a chronic condition [27]; in line with this definition, both self-monitoring and self-dosage of medication are considered important self-management skills in the PORTALS study.

Methods

Study design

For the PORTALS study, we designed a quality improvement intervention and compared strategies in an implementation study [28]. Two methods were developed to train long-term VKA patients of the Saltro Thrombosis Service (outpatient anticoagulation clinic and laboratory) in self-management routine care. Using this design, we aimed to examine the influence of the training strategy on clinical outcomes and usage of the supporting eHealth platform. Full methodological details are reported elsewhere [29]; Table 1 presents an overview of the study design.

Table 1. Overview of the study design: details of groups 1, 2 and 3

Saltro Thrombosis Service Centre			
		Self-Management	Usual Care
Patients	Group 1	Group 2	Group 3
	#72	#72	#72
Instruction	E-Learning Disease-specific knowledge Self-testing skills Use of the web-portal (voluntary) Self-adjustment of medication	Group Course Disease-specific knowledge Self-testing skills Use of the web-portal (voluntary) Self-adjustment of medication	Basic Short Training
Platform	Self-management	Self-management	

A parallel cohort design was used to investigate determinants of optimal implementation of self-management by comparing two different training methods. After inclusion, participants were randomly divided into subgroups: one group was trained and educated by e-learning (group 1) and the other group received face-to-face group training (group 2). Patients unable or unwilling to dose

1
2
3 their medication were free to continue with only self-monitoring. Patients who did not wish to start
4 with self-management were invited to participate in the non-self-management group, i.e. a parallel
5 cohort group receiving usual care (group 3). Group 3 provided valuable information about the
6 patients who were unable/unwilling to use an online supported self-management program.
7
8

9
10
11 Based on our parallel cohort design, comparison between e-learning and group training for self-
12 management (group 1 and 2) and non-self-management patients (group 3) is applicable, considering
13 the specific conditions in the choice of the statistics.
14

15 16 17 18 Participants

19 The present study focused on patients of the Salthro Thrombosis Service who voluntarily chose to
20 start with self-management. The inclusion criteria for patients to start with self-management were a
21 long-term indication for anticoagulants, internet access, and stable INR values (at least three INR
22 values in succession must be within therapeutic range). Patients who met the criteria for self-
23 management were approached for participation in the study. Because self-management (including
24 eHealth) is already an option for patients of the Salthro Thrombosis Service, the group training was
25 also open to patients who were not willing to participate in the study. The e-learning was reserved
26 for participants of the present study, as this was a new implementation method. All patients
27 provided written informed consent before participation in the study.
28
29
30
31
32
33

34 35 36 Patient involvement

37 Patients were neither involved in the design, nor in defining research questions and outcome
38 measures of the study; however, they were actively involved in the development of the self-
39 management platform Portavita. To maximize the involvement of patients we did not randomize the
40 intervention groups (self-management and usual care); we chose a recruitment design in which
41 patients of the Thrombosis Service voluntarily chose to start with self-management. During the study
42 patients could give feedback on the intervention and on the self-management platform; their
43 satisfaction was continuously monitored. Feedback from patients made it possible to optimize their
44 care. All patients will be informed about the results of this study.
45
46
47
48
49
50

51 52 53 Recruitment of patients and non-participation

54 Patients of the Salthro Thrombosis Service who received regular care without a self-management
55 program were eligible for recruitment. In 2013, 8950 patients received usual care from the Salthro
56 Thrombosis Service of which 85% had a long-term indication. From June 2013 onward, a random
57
58
59
60

selection of 1632 patients was approached for participation in the present study using three methods, i) information and invitation by letter, ii) personal invitation by specialized nurses, and iii) invitation by telephone. Patients who did not wish to start with self-management were invited to participate in a parallel cohort group receiving usual care (group 3), thereby providing valuable information about non-participants. Baseline characteristics of all regular patients of the Saltro Thrombosis Service also provided valuable information about non-participants.

Intervention

The intervention in group 1 and 2 consisted of a training program in combination with the use of an online self-management portal called Portavita. In group 1, patients used an e-learning that was specifically designed for the PORTALS study (Multimedia Appendix 1).

Table 2 summarizes the programs in all groups: the e-learning modules in group 1, the group training modules in group 2, and the basic training in group 3. In group 1 the training was provided by e-learning that started with a personal login procedure and an online instruction; the interim control and quality checks were carried out by specialized nurses of the Thrombosis Service. The group course in group 2 was carried out by specialized and expert healthcare professionals. Both training methods had the same content, but were offered in a completely different manner.

Table 2. Training methods in group 1, 2 and 3.

Group 1	Group 2	Group 3
General education (e-learning) about anticoagulation + test Selftesting device Training (e-learning) selftesting + use of web portal Three months of e-learning + selftesting	Group course with training selftesting + use of web portal Three weeks practice at home Group course about anti coagulation Three months of training at home	Basic training
Selftesting device	Selftesting device	Venipuncture at home or in facilities

Control and quality check by nurse Continuing self-management program + Control and quality check by nurse every six months	Control and quality check by nurse Continuing self-management program + Control and quality check by nurse every six months	Written instructions by thrombosis doctor
---	---	---

In the PORTALS study, the online self-management portal used is called Portavita (Multimedia Appendix 2). This application combines a patient portal and a healthcare provider portal. The healthcare portal leaves space for the OAT protocol, medication records, and information about complications. The Portavita Anticoagulation Self-management patient portal has become widely accepted; it provides patients with a diary tool for self-monitoring and self-dosage, education, it also allows personal notes, and healthcare professionals can send advice and notes to the patient. It implies that the patient analyzes a drop of blood using a home INR monitor. The patient can access the web-based patient portal to enter the INR and specific information for the health professional (intervention, bleeding, change in medication, vacation, etc.). Clinically validated inbuilt algorithms provide advice regarding the next dose and test interval. The only things needed are an internet connection and a device like a PC, tablet or smartphone. When logging on (username + password) for the first time to Portavita, every user was directed to the homepage. From there, users could access all functionalities of the portal. The logon procedure of this portal is based on Dutch security legislation and guidelines (the Dutch Personal Data Protection Act).

Data collection

INR values, thromboembolic events, bleedings, medication and indication were monitored and registered continuously by patients in the portal and by professionals of the Saltro Thrombosis Service. We measured the INR, complications and medication during a period of 6 months before and 18 months after starting the intervention (i.e. 24 months in total). The data collection also consisted of questionnaires (at baseline, and after each 3 x 6-month period) to measure the determinants and outcomes. Patients of group 1 and 2 received these questionnaires by e-mail, and patients in group 3 by e-mail or by post. In addition, the number of self-tests and use of the portal were continuously registered in the portal. Data on the total population of the Saltro Thrombosis Service were also collected.

Outcome measures and determinants

The primary outcome of this study was therapeutic control expressed as the INR control over time and severe complications (bleedings and thromboembolic events). To summarize the INR control over time, the percentage of time in therapeutic range (TTR) of INR was used, calculated with the Rosendaal method [30]. TTR values were calculated for two INR ranges (INR 2-3 and INR 2-3.5) because different calculations are used in Dutch and in international guidelines. TTR was measured at four moments: at 6 months before intervention, and at 3 x 6-month periods (total of 18 months) after starting the intervention. Serious complications were defined as those needing treatment or medical evaluation. An independent thrombosis specialist was responsible for classifying serious complications at the end of the trial. The total follow-up period for all these measures was 24 months.

Furthermore, the self-management skills of participants were evaluated. Self-management skills were defined as usage of the self-management platform, reflected as the amount of login sessions. Self-monitoring and self-dosage are registered within the same login session. The usage counts were analyzed. The determinants were self-efficacy and socio-demographic characteristics. Self-efficacy was measured at baseline using the Generalized Self-Efficacy Scale (GSES), with items scored on a four-point scale with a higher score reflecting higher self-efficacy [31]. Socio-demographic characteristics were assessed by an online questionnaire addressing the following characteristics: age, gender, education level, marital status, working status (labor), and quality of life (QoL), which was assessed using the EuroQoL-5D (EQ-5D) and displayed at baseline. The EQ-5D is a 5-item questionnaire with a higher score reflecting a higher QoL.

Sample size and statistical methods

To detect a relevant effect of the new implementation strategy of e-learning or group training (>5%) [32] at a power 80% and $\alpha=0.05$, we calculated that a sample size of 63 patients was required per group. Considering a 15% drop out, 72 (63/0.85) patients were needed per study group. Baseline characteristics between the three groups were explored using Chi-square tests and Kruskal-Wallis tests.

To investigate the effect of the different implementation methods of training versus the parallel cohort group on TTR, multilevel linear regression modeling (mixed models) was used. First, TTR outcomes were compared between the three groups. A second (mixed models) analysis was used to compare the difference in effect between e-learning and group training (group 1 vs. group 2) on TTR.

The variable TTR was included as outcome in the model. The periods of TTR measurements (time), the group and the interaction term (time*group) were included as predictors.

Both analyses were adjusted for age and gender.

To examine the impact of GSES and education on the effect of the different implementation methods, multiple linear regression analyses were performed with TTR at time point 3 as outcome, and GSES and education as predictors. Analyses were adjusted for age and gender.

A linear regression analysis was used to analyze usage (mean number of login sessions) of the portal Portavita in group 1 and 2.

Results

A total of 1632 VKA patients of the Saltro Thrombosis Service were invited to participate, of which 56% (n=915) declined (Figure 1). Patients were invited in three different ways: by letter (n=475), by personal invitation during a visit to the Thrombosis Service (n=692) and by telephone (n=465). 717 patients were interested in participation in the study; 247 patients eventually signed an informed consent. During the process of inviting patients for the PORTALS study, patients were asked about their reasons for not participating: the main reasons were not having a computer or internet, no digital skills, the effort of participating in a trial, and their high level of satisfaction with usual care.

Participants were included in the study only after providing written informed consent but, because some patients failed to do this, 247 participants were finally included. Of these, 110 continued to receive regular care (group 3) and 137 patients were randomly divided into group 1 and 2 using a computer program. After randomization, 63 patients were included in group 1 (e-learning) and 74 in group 2 (group training). Figure 1 summarizes the recruitment process, including the reasons for loss to follow-up.

Characteristics of the total population of the Thrombosis Service

The characteristics of all VKA patients of the Saltro Thrombosis Service in 2015 are shown in Table 3.

Table 3. Clinical characteristics of the population of the Saltro Thrombosis Service.

Total patients N	11132
-------------------------	-------

Male N (%)	6009 (54.0)
Self-management N (%)	1986 (17.8)
Male self-management N (%)	1260 (63.4)
Medication	
Acenocoumarol N (%)	8360 (75.1)
Phenprocoumon N (%)	2761 (24.8)
Warfarin N (%)	11 (0.1)
Indications	
AF N (%)	7430 (66.8)
Ven thromboembolism N (%)	1673 (15.0)
Artificial valve N (%)	720 (6.5)
Other N (%)	1309 (11.8)
Severe complications	
Major bleedings N (%)	219 (2.0)
Thromboembolism N (%)	85 (0.8)

Baseline characteristics of study participants

Table 4 presents the baseline characteristics of the participants: median age was 66.9 years, and median TTR was 54.7 (for INR range 2-3) and 79.1 (for INR range 2-3.5). Of these patients, 66% had an indication of AF and 77.3% used acenocoumarol as oral anticoagulation medication. No significant differences were found between the three groups for gender ($\chi^2=0.38$, $p=0.826$), TTR ($\chi^2=3.68$, $p=0.159$), indication ($\chi^2=8.33$, $p=0.215$), and marital status ($\chi^2=7.47$, $p=0.280$). The three groups differed significantly in age ($\chi^2=19.96$, $p=0.000$), baseline GSES ($\chi^2=15.08$, $p=0.001$) and EQ-5D ($\chi^2=6.66$, $p=0.036$), use of medication ($\chi^2=15.23$, $p=0.004$), education level ($\chi^2=23.72$, $p=0.000$), and work status ($\chi^2=13.01$, $p=0.043$) (Table 4).

Table 4. Baseline characteristics of patients with VKA therapy in the PORTALS study

	Group 1	Group 2	Group 3	p-value	Total
N	63	74	110		247
Age in years* [IQR]	65.0 ^a [56.2-67.7]	65.8 ^a [56.4-70.4]	69.6 ^b [64.0-74.9]	0.00**	66.9 [59.5-72.7]
Males N (%)	47 (74.6)	52 (70.3)	81 (73.6)	0.826	180 (72.9)
TTR INR range 2-3 (%)* [IQR]	50.2 [39.1-67.1]	52.9 [39.0-68.6]	57.4 [40.1-75.1]	0.159	54.7 [39.8-70.7]
TTR INR range 2-3.5 (%)* [IQR]	76.3 [67.0-86.0]	77.1 [64.1-85.3]	85.6 [72.0-93.5]	0.159	79.1 [68.2-88.8]

	GSES* [IQR]	3.5 ^a [3.1-3.8]	3.3 ^{a,b} [3.0-3.7]	3.1 ^b [2.9-3.5]	0.001**	3.3 [3.0-3.7]
	EQ5D* [IQR]	1.0 ^a [0.81-1.0]	0.84 ^{a,b} [0.78-1.0]	0.84 ^b [0.78-1.0]	0.036**	0.84 [0.81-1.0]
	Indication					
	AF N (%)					
	Ven thromboembolism N (%)	42 (66.7)	44 (59.5)	77 (70.0)	0.215	163 (66)
	Artificial valve N (%)	13 (20.6)	18 (24.3)	11 (10.0)		42 (17)
	Other N (%)	2 (3.2)	3 (4.1)	4 (3.6)		9 (3.6)
		6 (9.5)	9 (12.2)	18 (16.4)		33 (13.4)
	Medication					
	Acenocoumarol N (%)	51 (81) ^a	64 (86.5) ^a	76 (69.1) ^b	0.004**	191 (77.3)
	Phenprocoumon N (%)	10 (15.9) ^a	10 (13.5) ^a	34 (30.9) ^b		54 (21.9)
	Warfarin N (%)	2 (3.2) ^a	0 (0) ^a	0 (0) ^a		2 (0.8)
	Education level					
	Low N (%)	7 (12.1) ^a	13 (19.1) ^a	33 (35.9) ^b	0.00**	53 (24.3)
	Medium N (%)	24 (41.4) ^a	32 (47.1) ^a	46 (50.0) ^a		102 (46.8)
	High N (%)	27 (46.6) ^a	23 (33.8) ^b	13 (14.1) ^c		63 (28.9)
	Marital status					
	Married N (%)	49 (84.5)	50 (73.5)	73 (79.3)	0.280	172 (78.9)
	Widow N (%)	1 (1.7)	6 (8.8)	4 (4.3)		11 (5.0)
	Divorced N (%)	1 (1.7)	6 (8.8)	4 (4.3)		11 (5.0)
	Single N (%)	7 (12.1)	6 (8.8)	11 (12.0)		24 (11.0)
	Labour					
	No paid work N (%)	28 (48.3) ^a	29 (42.6) ^a	39 (42.4) ^a	0.043**	96 (44.0)
	Paid work N (%)	19 (32.8) ^a	20 (29.4) ^a	14 (15.2) ^b		53 (24.3)
	Household N (%)	8 (13.8) ^a	11 (16.2) ^a	23 (25.0) ^a		42 (19.3)
	Incapacitated N (%)	3 (5.2) ^a	8 (11.8) ^a	16 (17.4) ^a		27 (12.4)

*Values are medians and corresponding Interquartile Ranges [IQR]

** Between-group differences (P < 0.05) are indicated by **

Each superscript (a,b,c) letter denotes a subset of sample categories which do not differ significantly from each other at the 0.05 level.

TTR is the therapeutic international normalized ratio (INR) range, GSES is the General Self-efficacy Scale, EQ5D EuroQol five dimensions questionnaire is a standardized instrument for use as a measure of health outcome.

N Missing questionnaires: GSES 29, EQ5D 32, indication 0, medication 0, education 29, marital status 29, labour 29.

Therapeutic control before and after intervention

Figure 2A shows the TTR values using the INR 2-3 in the three groups, 6 months before the intervention and in the 3 x 6-month periods after the intervention; the TTR values using the INR 2-3.5 are presented in Figure 2B (Appendix 3).

Analysis of the three groups showed no significant difference in TTR values over time ($F_{3,631}=0.755$, $p=0.520$), between the groups ($F_{2,211}=0.924$, $p=0.398$), or between the groups over time ($F_{6,631}=1.009$, $p=0.418$).

Analysis of the two self-management groups showed no significant differences in TTR values between the four time periods ($F_{3,378}=0.602$, $p=0.614$). Also, no significant differences in TTR were found between group 1 and 2 ($F_{3,378}=0.548$, $p=0.460$) or between these two groups over time ($F_{3,378}=1.335$, $p=0.263$).

The sensitivity analyses showed that using an INR of 2-3.5, instead of 2-3, had no marked effect on the results, although a significant time effect was found. Results are presented in figure 2B in Appendix 3.

During the 18-month period after the intervention, across all three groups, a total of 3 severe complications occurred (3/247=1.2%): i.e. two muscular bleedings in the e-learning group (2/63=3.2%) and one cerebrovascular accident among patients receiving group training (1/74=1.4%); no complications occurred in the usual care group.

Educational level and GSES

Educational level was not associated with the TTR in the last 6 months ($F_{2,198}=2.263$, $p=0.107$); education level did not modify the effect of the different implementation methods on TTR ($F_{4,198}=1.659$, $p=0.161$).

No association was found between the GSES and TTR in the last 6 months ($F_{1,198}=0.132$, $p=0.717$); GSES did not modify the effect of the different implementations methods on TTR ($F_{2,198}=1.762$, $p=0.174$).

Usage of the platform

Figure 3 presents the usage by patients in group 1 and 2 (using the logfiles of the Portavita platform) during the 18 months after start of the intervention. Patients logged on to the platform to register

1
2
3 their INR; some also used it to establish their medication dosage or to communicate with healthcare
4 professionals of the Thrombosis Service. There was no significant difference between group 1 and 2
5 in usage of the platform during the three time periods (0-6 months: mean 20.75 , SD 5.20 , $F_{1,109}$
6 =0.091, $p=0.764$; 6-12 months: mean 13.00, SD 7.0, $F_{1,109}=0.029$, $p=0.866$; 12-18 months: mean 12.5,
7 SD 7.39, $F_{1,109}=1.28$, $p=0.260$).
8
9
10

11 Discussion

12 In the present study, no differences were found in therapeutic control and usage of the platform
13 between anticoagulation self-management patients trained by e-learning and by group training.
14 Moreover, the clinical results for self-management patients were similar to those of patients
15 receiving regular care. Therefore, we conclude that, with adequate training through e-learning or
16 group training, self-management is safe and reliable for a selected proportion of motivated patients
17 receiving VKA. The PORTALS study provides valuable information on different implementation
18 methods of OAT self-management, including eHealth.
19
20
21
22
23
24
25
26
27
28

29 Strengths and limitations

30 This PORTALS study has several strengths. First, the study investigates the effect of different
31 education programs in a situation as close to 'real life' as possible, integrated in a self-management
32 program including eHealth, on clinical outcomes and self-management skills. The study also adds
33 evidence to the existing body of knowledge on implementation of eHealth; this is important because
34 local political/financial factors have a major impact on successful integration of eHealth in daily
35 practice and because self-management is important for patients who will use VKAs in the future [33].
36
37
38
39
40
41

42 This study also has limitations. First, a randomized controlled trial (RCT) was not feasible in our
43 setting of an implementation design in a real-life healthcare system with patients who have differing
44 demands. Instead, an observational study was considered the best option for our context, i.e.
45 patients cannot be denied or forced to start with self-management. Furthermore, self-management
46 skills imply behavioral changes. However, behavioral changes require time, whereas the study period
47 was restricted to 18 months. This study also has limitations typically associated with eHealth trials.
48 For example, as patients were free to volunteer, bias might have occurred in our study groups. Users
49 were self-selected and were, presumably, motivated to use the education program (including the
50 web-based platform) as would be expected in a real-life setting. Of the 1632 invited OAT patients,
51 247 patients (15%) were willing to participate and provided informed consent. However, only 137
52
53
54
55
56
57
58
59
60

1
2
3 patients (8.4% of invited patients) wanted to participate in the self-management groups and were
4 randomized; other studies have a similar low recruitment rate for self-management trials [34]. This
5 phenomenon might have affected the measurability of differences and might also reduce differences
6 between the groups. The high number of participants lost to follow-up in our study (“law of
7 attrition”; the phenomenon of participants stopping usage) is a common finding in eHealth
8 evaluations and one of the fundamental and methodological challenges in the evaluation of eHealth
9 apps [35]. The loss to follow-up is high with a risk of biased results due to user bias; therefore, these
10 results are only applicable for users of eHealth.

11
12 The total population of the Thrombosis Service showed a lower percentage of men than the
13 participants of the present study, although the distribution of indications/medication was similar. In
14 the total population, the percentage of severe complications was low (bleedings 2%,
15 thromboembolism 0.8%); during our study period the percentage of complications was also low
16 (group e-learning =3.2%; group training =1.4%; group usual care =0%), indicating a high quality of
17 thrombosis care.

18
19 During the process of inviting patients for the PORTALS study, we asked their reasons for not
20 participating (main reasons were: not having a computer/internet, no digital skills, the effort of
21 participating, and their high level of satisfaction with usual care). The group with usual care differed
22 significantly from the self-management groups on several baseline characteristics: i.e. patients in
23 usual care were older, had a lower education level, and fewer of them had paid work. Also, they had
24 a lower GSES and EQ5D, and made less use of acenocoumarol. Patients in the total population of the
25 Thrombosis Service, and in the usual care group, might have different wishes and expectations
26 towards care than patients that chose for a self-management program; i.e. self-management
27 programs are suitable for patients that are highly motivated and have skills for self-management
28 tasks.

29
30 Finally, to measure a significant difference in therapeutic control, 72 patients were needed in each
31 group. Although these numbers were not entirely met in group 1 (e-learning), analysis of the groups
32 should be sufficiently powered to detect relevant differences. In addition, the high number of INR
33 data points collected before and after the intervention has a substantial impact on the strength of
34 the design and the multilevel linear analysis.

35
36 Due to these limitations, caution is required when generalizing our results to general practice.
37 However, the practical applicability of our results for other specialized OAT centers is positive, i.e. the

1
2
3 study provides practical insight into successful implementation of self-management programs
4 consisting of high-quality training and usage of a patient platform.
5
6
7

8 Interpretation of findings 9

10 No overall significant differences in therapeutic control were found between the three groups; also,
11 there was no difference in therapeutic control between the group with e-learning and group training.
12 Therapeutic INR control was good in all groups; in the last 6 months of the intervention period, all
13 groups spent around 58% of time within the narrow therapeutic range 2-3 and 83% of time within
14 the therapeutic range 2-3.5; this indicates high quality and is comparable to other studies [34] [36].
15 Anticoagulation control levels around 60% for TTR of INR range 2-3 are considered safe [36] [37] [38].
16 In studies conducted outside specialized care facilities in several different regions, TTR ranged from
17 40-70% [13]. The national guidelines for the INR range changed during the last 6 months of our
18 PORTALS study; this had a negative impact on the TTR during our last measurement period.
19 Complication rates also compared favorably with international data; our overall adverse event rate
20 was low compared to other studies [39] [40] [41].
21
22

23 In comparison to literature, the baseline quality of OAT management in the present study can be
24 considered high in all groups; therefore, further improvement through a self-management program
25 including education was difficult to achieve and the outcomes in the groups remained the same.
26 Finally, both training methods were comparable on the effect of anticoagulation control; for patients
27 and healthcare professionals this means that a good e-learning program is a good alternative for
28 labour intensive group trainings. Based on our study, we recommend considering self-management
29 programs supported by e-learning as the preferred plan of action for self-management for
30 anticoagulation patients. Furthermore, self-management with an e-learning component is suitable
31 for motivated patients with sufficient digital skills; in our opinion, regular anticoagulation care needs
32 to remain available for the rest of the population.
33
34
35
36
37
38
39
40
41
42
43
44

45 Self-efficacy and educational level of users had no impact on therapeutic control for the different
46 implementation methods. The construct of perceived self-efficacy reflects an optimistic self-belief
47 [31]; a correlation can be understood based on the belief that one can perform a novel or difficult
48 task, or cope with adversity (indicating a higher self-efficacy). In the present study, self-efficacy was
49 comparable to that in a healthy Dutch population [42] [43].
50
51
52
53
54

55 The practical value of the Portavita portal is very high for patients, because of the functionalities of
56 self-monitoring, self-dosage and digital advice from professional healthcare providers. Because
57
58
59
60

1
2
3 patients use the self-management program, regular visits to medical facilities are unnecessary.
4 Patients can manage their anticoagulation in their own time and in their own chosen place. Thus,
5 using the self-management program gives them (extra) freedom; this might be a strong motivating
6 factor for using the program. Also, the training programs were sound and sustainable during the
7 entire study period, probably stimulating patients to persevere with their self-management program.
8 Moreover, e-learning and group training led to the same usage and, therefore, the same self-
9 management skills. Therefore, we conclude that our e-learning and group training provide a good
10 start for OAT patients that voluntarily start with a self-management program including eHealth.
11
12

13
14
15
16
17 Self-management programs with eHealth technologies for chronic conditions can be used to enhance
18 self-management and revise the Chronic Care Model; patients who actively participate in their care
19 achieve valuable and sustained improvement in wellbeing [44] [45]. In many eHealth studies, use of a
20 Personal Health Record or self-management platform can promote an informed/activated patient
21 and augment the Chronic Care Model for self-management support and productive interactions;
22 even though a direct dosage-effect relation (usually analyzed in a classical RCT) is not common in
23 eHealth [46]. Self-management programs with good training and practical eHealth platforms have
24 the potential to make chronic care personalized in a blended care model; every patient needs a
25 different approach for optimal therapeutic control. Healthcare providers need to embrace a different
26 role and release tight protocols [47]. Individual patients have different expectations and wishes,
27 which should be a topic of conversation with each patient. The general scientific basis for self-
28 management applies perfectly to anticoagulation patients, which is confirmed in our study.
29
30
31
32
33
34
35
36
37

38 More studies are needed (preferably with larger sample groups, and including non-users) to gain
39 more insight into the preferences of various patient groups, as well as the related costs.
40 The substantial workload generated by integrating a web-based platform in an OAT self-management
41 program emphasizes the importance of piloting and assessing workforce implications for OAT
42 management centers. The present results provide additional insight into the organizational aspects
43 of the implementation of education programs into a self-management program with a platform,
44 including the need to educate and coach patients in the use of web-based platforms.
45
46
47
48
49
50

51 Conclusion

52
53 Our main finding is that there were no differences in therapeutic control and usage of a supporting
54 eHealth platform between anticoagulation self-management patients trained by e-learning and by
55 group training. Moreover, we found that clinical results for self-management patients are
56
57
58
59
60

1
2
3 comparable to those of patients receiving usual care. We conclude that with appropriate and sound
4 training through e-learning or group training, self-management seems safe and reliable for a selected
5 proportion of motivated patients receiving oral anticoagulation treatment. The PORTALS study
6 provides valuable information on different implementation methods of oral anticoagulation self-
7 management, including eHealth.
8
9
10

11 Acknowledgments

12 The authors wish to thank all patients and caregivers within the Saltro Thrombosis Service Centre.
13 The authors thank Pim Assendelft for his valuable contribution to the design and Joke van der Feest,
14 Nynke Wiersma, Carola Guse and Sandra Claassen for their research assistance. The authors also
15 thank Nan van Geloven for reviewing the statistical analysis.
16
17
18
19
20
21
22

23 Data sharing

24 Data will be made available for sharing where available and appropriate.
25
26
27
28

29 Transparency declaration

30 The lead author affirms that the manuscript is an honest, accurate, and transparent account of the
31 study being reported; that no important aspects of the study have been omitted; and that any
32 discrepancies from the study as planned (and, if relevant, registered) have been explained.
33 All authors, external and internal, had full access to all of the data (including statistical reports and
34 tables) in the study and can take responsibility for the integrity of the data and the accuracy of the
35 data analysis.
36
37
38
39
40
41
42

43 Ethics and consent to participate

44 This study is conducted according to the principles of the Declaration of Helsinki (version 59, 2008)
45 and in accordance with the Medical Research Involving Human Subjects Act (WMO). Participants
46 were only included in the study after written informed consent was received. The Medical Ethics
47 Committee of the LUMC approved this study (Reference No. P12.278).
48
49
50
51
52

53 Competing interests

54 All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf
55 and declare: no support from any organization for the submitted work; no financial relationships
56
57
58
59
60

1
2
3 with any organizations that might have an interest in the submitted work in the previous three years;
4 no other relationships or activities that could appear to have influenced the submitted work.
5
6
7

8 Funding

9
10 This work was supported by the Foundation Care Within Reach (in Dutch: Stichting Zorg Binnen
11 Bereik).
12

13 Author's contributions

14
15 ET is the principle investigator and contributed to all aspects of the research. NV assisted on all
16 aspects. MK assisted on the statistical analysis and is responsible for revising the manuscript several
17 times. LH is responsible for revising the manuscript several times. IT is responsible for the acquisition
18 of data and revising the manuscript several times. MN is responsible for revising the manuscript. NC
19 is responsible for the concept, design, and for revising the manuscript. All authors read and approved
20 the final manuscript.
21
22
23
24
25
26
27
28

29 Figure legends

30
31 Figure 1. Flowchart of the PORTALS study.
32

33 Figure 2A. Health status based on time in therapeutic (TTR) (for INR range 2-3) for the three groups.
34

35 Figure 3. Usage of the platform in group 1 and group 2 after start of the intervention.
36
37
38

39 References

- 40
41 1. Streiff MB, Carolan HT, Hobson DB, Kraus PS, Holzmueller CG, Demski R, Lau BD, Biscup-Horn P,
42 Pronovost PJ, Haut ER. Lessons from the Johns Hopkins Multi-Disciplinary Venous Thromboembolism
43 (VTE) Prevention Collaborative. *BMJ*. 2012 Jun 19;344:e3935. DOI: 10.1136/bmj.e3935.
- 44
45 2. CBO Richtlijn Diagnostiek, preventie en behandeling van Veneuze trombo-embolie en Secundaire
46 Preventie Arteriele trombose 2009 [*CBO Diagnostics Guidelines, prevention and treatment of venous*
47 *thromboembolism and secondary prevention of arterial thrombosis 2009*].
- 48
49 3. Schnabel RB et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and
50 mortality in the Framingham Heart Study: a cohort study. *Lancet* , Volume 386 , Issue 9989 , 154 –
51 162. July 2015. DOI: [http://dx.doi.org/10.1016/S0140-6736\(14\)61774-8](http://dx.doi.org/10.1016/S0140-6736(14)61774-8).
- 52
53 4. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek ME, Schulman S, Go AS,
54 Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GYH. Antithrombotic Therapy for Atrial
55
56
57
58
59
60

1
2
3 Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of
4 Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2_suppl):e531S-e575S.
5 doi:10.1378/chest.11-2304.

6
7
8 5. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel
9 JP. Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal
10 Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After
11 Isolated Calf Deep Vein Thrombosis. *Circulation* May 22, 2001, Volume 103, Issue 20. doi:
12
13
14 <https://doi.org/10.1161/01.CIR.103.20.2453>.

15
16 6. Torn M, Bollen WLE, Meer van der FJM, Wall van der EE, Rosendaal FR. Risks of Oral Anticoagulant
17 Therapy With Increasing Age. *Arch Intern Med*. 2005;165:1527-1532.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
doi:10.1001/archinte.165.13.1527.

7. Heneghan C, Ward A, Perera R, Self-Monitoring Trialist Collaboration, Bankhead C, Fuller A, et al.
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient
data. *Lancet* 2012 Jan 28;379(9813):322-334 doi: 10.1016/S0140-6736(11)61294-4.

8. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of Intensity of Oral
Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. *N Engl J Med* 2003;349:1019-
26. DOI: 10.1056/NEJMoa022913.

9. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in
patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis.
Blood 2014 124:2450-2458; doi: <https://doi.org/10.1182/blood-2014-07-590323>

10. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E.
Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart Valves. *N Engl J Med* 1995;
333:11-17. July 6, 1995. DOI: 10.1056/NEJM199507063330103.

11. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI,
Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, Nguyen P, Demers C, Kahn SR, Kassis J,
Rodger M, Hambleton J, Gent M. Comparison of Low-Intensity Warfarin Therapy
with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous
Thromboembolism. *N Engl J Med* 349;7. DOI: 10.1056/NEJMoa035422.

12. Kimmel SE, Chen Z, Price M, Gross R. The Influence of Patient Adherence on Anticoagulation
Control With Warfarin; Results From the International Normalized Ratio Adherence and Genetics (IN-
RANGE) Study. *Arch Intern Med*. 2007;167(3):229-235. DOI: 10.1001/archinte.167.3.229.

13. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC,
Breithard G, Hankey JG, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KAA. Impact of Global

1
2
3 Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the
4 ROCKET AF Clinical Trial. *J Am Heart Assoc.* 2013;2:e000067 doi: 10.1161/JAHA.112.000067.

5
6 14. McLean S, Protti D, Sheikh A. Telehealthcare for long-term conditions. *BMJ* 2011;342:d120. doi:
7 10.1136/bmj.d120.

8
9 15. Gadisseur APA, Kaptein AA, Breukink-Engbers WGM, van der Meer FJM, Rosendaal FR. Patient
10 self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics:
11 positive effects on quality of life. *J Thromb Haemost* 2004 Apr;2(4):584-591. DOI: 10.1111/j.1538-
12 7836.2004.00659.x.

13
14 16. McCahon D, Murray ET, Murray K, Holder RL, Fitzmaurice DA. Does self-management of oral
15 anticoagulation therapy improve quality of life and anxiety? *Fam Pract* 2011 Apr;28(2):134-140.
16 DOI: 10.1093/fampra/cmq089.

17
18 17. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, Alonso-Coello P,
19 Fitzmaurice D, Mahtani KR, Onakpoya IJ. Self-monitoring and self-management of oral
20 anticoagulation. *Cochrane Heart Group* 2016. DOI: 10.1002/14651858.CD003839.pub3.

21
22 18. Newman S, Steed L, Mulligan K. Self-management interventions for chronic illness. *Lancet* 2004;
23 364: 1523–37. DOI: 10.1016/S0140-6736(04)17277-2.

24
25 19. Bouillon K, Bertrand M, Maura G, Blotière PO, Ricordeau P, Zureik M. Risk of bleeding and arterial
26 thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K
27 antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-
28 cohort study. *Lancet Haematol* 2015 Apr;2(4):e150-9. doi: 10.1016/S2352-3026(15)00027-7.

29
30 20. Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, et al. Safety and effectiveness of
31 oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein
32 thrombosis (XALIA): An international, prospective, non-interventional study. *Lancet Haematol*
33 2016;3:e12-21 . doi: 10.1016/S2352-3026(15)00257-4.

34
35 21. Lin L, Lim WS, Zhou HJ, Khoo AL, Tan KT, Chew AP, et al. Clinical and safety outcomes of oral anti-
36 thrombotics for stroke prevention in atrial fibrillation: A systematic review and network meta-
37 analysis. *J Am Med Dir Assoc* 2015;16:1103.e1-19. doi: 10.1016/j.jamda.2015.09.008.

38
39 22. Lorig K, Ritter P, Stewart A, Sobel D, Brown B, Bandura A, Gonzalez V, Laurent D, Holman H.
40 Chronic Disease Self-Management Program. 2-Year Health Status and Health Care Utilization
41 Outcomes. *Med Care.* 2001 Nov;39(11):1217-23. PMID: 11606875.

42
43 23. Mishali M, Omer H, Heymann A. The importance of measuring self-efficacy in patients with
44 diabetes. *Fam Pract.* 2011 Feb;28(1):82-7. doi: 10.1093/fampra/cmq086.

45
46 24. Simpson E, Jones MC. An exploration of self-efficacy and self-management in COPD patients. *Br J*
47 *Nurs.* 2013 Oct 24-Nov 13;22(19):1105-9. DOI: 10.12968/bjon.2013.22.19.1105

- 1
2
3 25. Rajati F, Sadeghi M, Feizi A, Sharifirad G, Hasandokht T, Mostafavi F. Self-efficacy strategies to
4 improve exercise in patients with heart failure: A systematic review. *ARYA Atheroscler*. 2014
5 Nov;10(6):319-33. PMID: 25815022.
6
7 26. Kontos E, Blake KD, Chou WYS, Prestin A. Predictors of eHealth Usage: Insights on The Digital
8 Divide From the Health Information National Trends Survey 2012. *J Med Internet Res*
9 2014;16(7):e172. doi:10.2196/jmir.3117.
10
11 27. Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches for people
12 with chronic conditions: a review. *Patient Educ Couns* 2002; 48: 177–87. PMID: 12401421
13
14 28. van Bokhoven MA, Kok G, van der Weijden T. Designing a quality improvement intervention: a
15 systematic approach. *Qual Saf Health Care*. 2003;12:215–20. PMID: 12792013
16
17 29. Talboom EPWA, Verdijk NA, Talboom IJSH, Harmans LM, Numans ME, Chavannes NH. PORTALS:
18 design of an innovative approach to anticoagulation management through eHealth. *BMC Health*
19 *Services Research* (2017) 17:213 DOI 10.1186/s12913-017-2142-2
20
21 30. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal
22 intensity of oral anticoagulant therapy. *Thromb Haemost*. 1993;69(3):236–9. PMID: 8470047
23
24 31. Scholz U, Gutiérrez-Doña B, Sud S, Schwarzer R. Is general self-efficacy a universal construct?
25 Psychometric findings from 25 countries. *Eur J Psychol Assess*. 2002;18:242–51.
26
27 32. Heneghan C, Ward A, Perera R et al. Self-monitoring of oral anticoagulation: systematic review
28 and meta-analysis of individual patient data. *Lancet*. 2012 Jan 28;379(9813):322-34. DOI:
29 10.1016/S0140-6736(11)61294-4
30
31 33. Nijland N. Thesis: Grounding eHealth. Towards an holistic framework for sustainable eHealth
32 technologies. University of Twente; 2011. ISBN: 9789036531337
33
34 34. Gadisseur AP, Breukink-Engbers WG, Meer van der FJ, Besselaar van den AM, Sturk A, Rosendaal
35 FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and
36 management by specialized anticoagulation clinics in the Netherlands: a randomised clinical trial.
37 *Arch Int Med* 2003;163:2639-46. DOI: 10.1001/archinte.163.21.2639
38
39 35. Eysenbach G. The Law of Attrition. *J Med Internet Res* 2005;7(1):e11. PMID: 15829473
40
41 36. Menéndez-Jándula B, Souto JC, Oliver A, Montserat I, Quintana M, Gich I, et al. Comparing self-
42 management of oral anticoagulant therapy with clinic management: a randomized trial. *Ann Intern*
43 *Med* 2005;142:1-10. PMID: 15630104.
44
45 37. Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S, et al. Self-management
46 of oral anticoagulation: randomised trial. *BMJ* 2005 Nov 5;331(7524):1057 doi:
47 10.1136/bmj.38618.580903.AE.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 38. Ryan F, Byrne S, O'Shea S. Randomized controlled trial of supervised patient self-testing of
4 warfarin therapy using an internet-based expert system. *J Thromb Haemost* 2009 Aug;7(8):1284-
5 1290. doi: 10.1111/j.1538-7836.2009.03497.x.
6
7
8 39. Rein van N, Lijfering WM, Bos MHA, Herruer MH, Vermaas HW, Meer van der FJM, Reitsma PH.
9 Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for
10 Major Bleeding during Treatment with Vitamin K Antagonists. *PLoS ONE* 11(12): e0164485.
11 doi:10.1371/journal.pone.0164485.
12
13 40. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage:
14 results from the National Registry of Atrial Fibrillation (NRAF). *Am Heart J* 2006;151(3):713-719. DOI:
15 10.1016/j.ahj.2005.04.017.
16
17 41. Chai-Adisaksoha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in
18 patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. *Blood*.
19 2014;124(15):2450-2458. DOI 10.1182/blood-2014-07-590323.
20
21 42. Schwarzer R. Self-efficacy: Thought Control of Action. Hemisphere Publishing Corporation; 1992.
22 ISBN: 9781560322696.
23
24 43. Luszczynska A, Gutiérrez-Doña B, Schwarzer R. General self-efficacy in various domains of human
25 functioning: Evidence from five countries. *Int J Psychol* 2005; 40 (2), 80–89.
26 doi: 10.1080/00207590444000041.
27
28 44. Siminerio LM. The role of technology and the chronic care model. *J Diabetes Sci Technol* 2010
29 Mar;4(2):470-475. DOI: 10.1177/193229681000400229.
30
31 45. Stellefson M, Chaney B, Barry AE, Chavarria E, Tennant B, Walsh-Childers K, et al. Web 2.0 chronic
32 disease self-management for older adults: a systematic review. *J Med Internet Res* 2013;15(2):e35.
33 doi: 10.2196/jmir.2439.
34
35 46. Archer N, Fevrier-Thomas U, Lokker C, McKibbin KA, Straus SE. Personal health records: a
36 scoping review. *J Am Med Inform Assoc* 2011;18(4):515-522. doi: 10.1136/amiajnl-2011-000105.
37
38 47. Sun X, Guyatt GH. Interventions to enhance self-management support. *BMJ* 2013;346:f3949. doi:
39 <https://doi.org/10.1136/bmj.f3949>.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flowchart of the PORTALS study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2A. Health status based on time in therapeutic (TTR) (for INR range 2-3) for the three groups.





Figure 3. Usage of the platform in group 1 and group 2 after start of the intervention.

BMJ Open: first published as 10.1136/bmjopen-2017-017909 on 27 September 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.



Appendix 1: E-learning anticoagulation

review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Selfmanagement, S.
 My details | Contact | Manual & Instructional videos | Log out

Homepage from Selfmanagement, S.

Personal data
 Patient number SELF01992765

Most recent dosing schedule (provisional)
 Dosing period: 28-03-2017 until 17-04-2017
 Anticoagulation medication: Acenocoumarol 1 mg
 Dosing schedule created on: 28-03-2017 by Selfmanagement, S.
 Dose according to step: 25

Important data
 Dosing schedule based on INR: 3,6 measured on Tue, 28-03-2017 at 06:46
 Next Thrombosis Service check-up: **Tue. 17-01-2017 at 09:00**
 Next blood sampling date: Tue. 18-04-2017


	wk. 13	wk. 14	wk. 15	wk. 16
Mon.		3 Apr. 2	10 Apr. 2	17 Apr. 2
Tue.	28 Mar. 1	4 Apr. 2	11 Apr. 1	18 Apr. 2
Wed.	29 Mar. 2	5 Apr. 2	12 Apr. 2	19 Apr. 2
Thu.	30 Mar. 2	6 Apr. 1	13 Apr. 2	20 Apr. 1
Fri.	31 Mar. 2	7 Apr. 2	14 Apr. 2	
Sat.	1 Apr. 1	8 Apr. 2	15 Apr. 1	
Sun.	2 Apr. 2	9 Apr. 2	16 Apr. 2	

Print dosing schedule | Print holiday letter | You will need Adobe Reader to view the holiday letters. You can download this program for free [here](#).

Subject (read message)	New messages from	Date	Time
Er is een opmerking bij uw doseschema toegevoegd of gewijzigd	Trombosedienst Demo	19-01-2017	12:48
test	Trombosedienst Demo	12-01-2017	16:18

Terms and Conditions | Marking | **PORTALS** Advanced Health

Appendix 2: Patients' self-management web portal homepage



Appendix 3: Health status based on time in therapeutic (TTR) (for INR range 2-3.5) for the three groups. Figure 2B shows TTR values using the INR 2-3.5 in the three groups, 6 months before the intervention and in the 3 x 6-month periods after the intervention. Analysis of the three groups showed that the TTR values differed significantly over time ($p=0.017$). No significant differences were found in TTR between the groups ($p=0.163$) or between the groups over time ($p=0.545$).

Analysis of the two self-management groups showed significant differences in the TTR values between the four time periods (i.e. pre- and postintervention) ($p=0.008$). There were no significant differences in TTR between group 1 and 2 ($p=0.721$) or between the groups over time ($p=0.825$).

Equivalent health status for e-learning, group training self-management or usual care in oral anticoagulation patients: a parallel cohort design in the PORTALS Study

STROBE statement, checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract		
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract – Page 1 (b) Provide in the abstract an informative and balanced summary of what was done and what was found – Page 2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported – Page 3 (Introduction)
Objectives	3	State specific objectives, including any prespecified hypotheses – Page 4 (Introduction)
Methods		
Study design	4	Present key elements of study design early in the paper – Page 5/6 (Study design) + figure 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection – Page 5 (Study design) + reference 28
Participants	6	(a) <i>Cohort study?</i> Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up – Page 6 (Participants) + reference 28
		(b) <i>Cohort study?</i> For matched studies, give matching criteria and number of exposed and unexposed Participants were not matched + figure 1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give

	Item No	Recommendation
		diagnostic criteria, if applicable – Page 8/9 (Outcome measures and determinants)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). – Page 8/9 (Outcome measures and determinants) Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias – Page 9 (Sample size and statistical methods)
Study size	10	Explain how the study size was arrived at – Page 9 (Sample size and statistical methods)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why – Page 8/9 (Outcome measures and determinants)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding – Page 9 (Sample size and statistical methods)
		(b) Describe any methods used to examine subgroups and interactions – Page 9 (Sample size and statistical methods)
		(c) Explain how missing data were addressed – Page 9 (Sample size and statistical methods)
		(d) Cohort study? If applicable, explain how loss to follow-up was addressed – Page 9 (Sample size and statistical methods)
		(e) Describe any sensitivity analyses Not applicable.
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study? eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed – Page 9/10 (Results)
		(b) Give reasons for non-participation at each stage – Page 10/11 (Baseline characteristics of study participants)
		(c) Consider use of a flow diagram Figure 2.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders – Page 10/11 (Baseline characteristics of study participants)

	Item No	Recommendation
		(b) Indicate number of participants with missing data for each variable of interest – Page 10/11 (Baseline characteristics of study participants) + Table 3
		(c) Cohort study? Summarise follow-up time (eg average and total amount) – Page 8/9 (Outcome measures and determinants)
Outcome data	15*	Cohort study? Report numbers of outcome events or summary measures over time – Page 12/13 (Usage of the platform)
Main results	16	(a) Report the numbers of individuals at each stage of the study? eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed – Page 9/10 (Results)
		(b) Give reasons for non-participation at each stage – Page 9/10 (Results)
		(c) Consider use of a flow diagram Figure 2.
Other analyses	17	Report other analyses done? eg analyses of subgroups and interactions, and sensitivity analyses Page 12 (Health status before and after intervention/Educational level and GSES)
Discussion		
Key results	18	Summarise key results with reference to study objectives – Page 13 (Discussion)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias – Page 13/14 (Strengths and limitations)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence – Page 14/15 (Interpretation of findings)
Generalisability	21	Discuss the generalisability (external validity) of the study results – Page 16 (Interpretation of findings)
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based – Page 17 (Funding)

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross sectional studies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The STROBE checklist is best used in conjunction with the explanation and elaboration article.¹⁸⁻²⁰ This article and separate versions of the checklist for cohort, case-control, and cross sectional studies are available at www.strobe-statement.org.

For peer review only